Illinois 2025-2026 Regular Session

Illinois House Bill HB2468 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2468 Introduced , by Rep. Barbara Hernandez SYNOPSIS AS INTRODUCED: 225 ILCS 95/4 from Ch. 111, par. 4604225 ILCS 95/6 from Ch. 111, par. 4606225 ILCS 95/7 from Ch. 111, par. 4607225 ILCS 95/7.5225 ILCS 95/7.7225 ILCS 95/7.8 new225 ILCS 95/7.9 new225 ILCS 95/20 from Ch. 111, par. 4620225 ILCS 95/21 from Ch. 111, par. 4621720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/303.05 Amends the Physician Assistant Practice Act of 1987. Provides that a physician assistant may prescribe, dispense, order, administer, and procure drugs and medical devices without delegation of authority by a physician. Provides that a physician assistant may practice without a written collaborative agreement. Provides that a physician assistant who files with the Department of Financial and Professional Regulation a notarized attestation of completion of at least 250 hours of continuing education or training and at least 2,000 hours of clinical experience after first attaining national certification shall not require a written collaborative agreement to practice. Makes changes in provisions concerning definitions; physician assistant title; collaboration requirements; written collaborative agreements, prescriptive authority, and physician assistants in hospitals, hospital affiliates, or ambulatory surgical treatment centers; inactive status; limitations; and grounds for disciplinary action. Amends the Illinois Controlled Substances Act to make corresponding changes. LRB104 10667 AAS 20746 b A BILL FOR 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2468 Introduced , by Rep. Barbara Hernandez SYNOPSIS AS INTRODUCED: 225 ILCS 95/4 from Ch. 111, par. 4604225 ILCS 95/6 from Ch. 111, par. 4606225 ILCS 95/7 from Ch. 111, par. 4607225 ILCS 95/7.5225 ILCS 95/7.7225 ILCS 95/7.8 new225 ILCS 95/7.9 new225 ILCS 95/20 from Ch. 111, par. 4620225 ILCS 95/21 from Ch. 111, par. 4621720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/303.05 225 ILCS 95/4 from Ch. 111, par. 4604 225 ILCS 95/6 from Ch. 111, par. 4606 225 ILCS 95/7 from Ch. 111, par. 4607 225 ILCS 95/7.5 225 ILCS 95/7.7 225 ILCS 95/7.8 new 225 ILCS 95/7.9 new 225 ILCS 95/20 from Ch. 111, par. 4620 225 ILCS 95/21 from Ch. 111, par. 4621 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/303.05 Amends the Physician Assistant Practice Act of 1987. Provides that a physician assistant may prescribe, dispense, order, administer, and procure drugs and medical devices without delegation of authority by a physician. Provides that a physician assistant may practice without a written collaborative agreement. Provides that a physician assistant who files with the Department of Financial and Professional Regulation a notarized attestation of completion of at least 250 hours of continuing education or training and at least 2,000 hours of clinical experience after first attaining national certification shall not require a written collaborative agreement to practice. Makes changes in provisions concerning definitions; physician assistant title; collaboration requirements; written collaborative agreements, prescriptive authority, and physician assistants in hospitals, hospital affiliates, or ambulatory surgical treatment centers; inactive status; limitations; and grounds for disciplinary action. Amends the Illinois Controlled Substances Act to make corresponding changes. LRB104 10667 AAS 20746 b LRB104 10667 AAS 20746 b A BILL FOR
2	2	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2468 Introduced , by Rep. Barbara Hernandez SYNOPSIS AS INTRODUCED:
3	3	225 ILCS 95/4 from Ch. 111, par. 4604225 ILCS 95/6 from Ch. 111, par. 4606225 ILCS 95/7 from Ch. 111, par. 4607225 ILCS 95/7.5225 ILCS 95/7.7225 ILCS 95/7.8 new225 ILCS 95/7.9 new225 ILCS 95/20 from Ch. 111, par. 4620225 ILCS 95/21 from Ch. 111, par. 4621720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/303.05 225 ILCS 95/4 from Ch. 111, par. 4604 225 ILCS 95/6 from Ch. 111, par. 4606 225 ILCS 95/7 from Ch. 111, par. 4607 225 ILCS 95/7.5 225 ILCS 95/7.7 225 ILCS 95/7.8 new 225 ILCS 95/7.9 new 225 ILCS 95/20 from Ch. 111, par. 4620 225 ILCS 95/21 from Ch. 111, par. 4621 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/303.05
4	4	225 ILCS 95/4 from Ch. 111, par. 4604
5	5	225 ILCS 95/6 from Ch. 111, par. 4606
6	6	225 ILCS 95/7 from Ch. 111, par. 4607
7	7	225 ILCS 95/7.5
8	8	225 ILCS 95/7.7
9	9	225 ILCS 95/7.8 new
10	10	225 ILCS 95/7.9 new
11	11	225 ILCS 95/20 from Ch. 111, par. 4620
12	12	225 ILCS 95/21 from Ch. 111, par. 4621
13	13	720 ILCS 570/102 from Ch. 56 1/2, par. 1102
14	14	720 ILCS 570/303.05
15	15	Amends the Physician Assistant Practice Act of 1987. Provides that a physician assistant may prescribe, dispense, order, administer, and procure drugs and medical devices without delegation of authority by a physician. Provides that a physician assistant may practice without a written collaborative agreement. Provides that a physician assistant who files with the Department of Financial and Professional Regulation a notarized attestation of completion of at least 250 hours of continuing education or training and at least 2,000 hours of clinical experience after first attaining national certification shall not require a written collaborative agreement to practice. Makes changes in provisions concerning definitions; physician assistant title; collaboration requirements; written collaborative agreements, prescriptive authority, and physician assistants in hospitals, hospital affiliates, or ambulatory surgical treatment centers; inactive status; limitations; and grounds for disciplinary action. Amends the Illinois Controlled Substances Act to make corresponding changes.
16	16	LRB104 10667 AAS 20746 b LRB104 10667 AAS 20746 b
17	17	LRB104 10667 AAS 20746 b
18	18	A BILL FOR
19	19	HB2468LRB104 10667 AAS 20746 b HB2468 LRB104 10667 AAS 20746 b
20	20	HB2468 LRB104 10667 AAS 20746 b
21	21	1 AN ACT concerning regulation.
22	22	2 Be it enacted by the People of the State of Illinois,
23	23	3 represented in the General Assembly:
24	24	4 Section 5. The Physician Assistant Practice Act of 1987 is
25	25	5 amended by changing Sections 4, 6, 7, 7.5, 7.7, 20, and 21 and
26	26	6 by adding Sections 7.8 and 7.9 as follows:
27	27	7 (225 ILCS 95/4) (from Ch. 111, par. 4604)
28	28	8 (Section scheduled to be repealed on January 1, 2028)
29	29	9 Sec. 4. Definitions. In this Act:
30	30	10 1. "Department" means the Department of Financial and
31	31	11 Professional Regulation.
32	32	12 2. "Secretary" means the Secretary of Financial and
33	33	13 Professional Regulation.
34	34	14 3. "Physician assistant" means any person not holding an
35	35	15 active license or permit issued by the Department pursuant to
36	36	16 the Medical Practice Act of 1987 who has been certified as a
37	37	17 physician assistant by the National Commission on the
38	38	18 Certification of Physician Assistants or an equivalent
39	39	19 successor agency. and performs procedures in collaboration
40	40	20 with a physician as defined in this Act. A physician assistant
41	41	21 may perform such procedures within the specialty of the
42	42	22 collaborating physician, except that such physician shall
43	43	23 exercise such direction, collaboration, and control over such
44	44
45	45
46	46
47	47	104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2468 Introduced , by Rep. Barbara Hernandez SYNOPSIS AS INTRODUCED:
48	48	225 ILCS 95/4 from Ch. 111, par. 4604225 ILCS 95/6 from Ch. 111, par. 4606225 ILCS 95/7 from Ch. 111, par. 4607225 ILCS 95/7.5225 ILCS 95/7.7225 ILCS 95/7.8 new225 ILCS 95/7.9 new225 ILCS 95/20 from Ch. 111, par. 4620225 ILCS 95/21 from Ch. 111, par. 4621720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/303.05 225 ILCS 95/4 from Ch. 111, par. 4604 225 ILCS 95/6 from Ch. 111, par. 4606 225 ILCS 95/7 from Ch. 111, par. 4607 225 ILCS 95/7.5 225 ILCS 95/7.7 225 ILCS 95/7.8 new 225 ILCS 95/7.9 new 225 ILCS 95/20 from Ch. 111, par. 4620 225 ILCS 95/21 from Ch. 111, par. 4621 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/303.05
49	49	225 ILCS 95/4 from Ch. 111, par. 4604
50	50	225 ILCS 95/6 from Ch. 111, par. 4606
51	51	225 ILCS 95/7 from Ch. 111, par. 4607
52	52	225 ILCS 95/7.5
53	53	225 ILCS 95/7.7
54	54	225 ILCS 95/7.8 new
55	55	225 ILCS 95/7.9 new
56	56	225 ILCS 95/20 from Ch. 111, par. 4620
57	57	225 ILCS 95/21 from Ch. 111, par. 4621
58	58	720 ILCS 570/102 from Ch. 56 1/2, par. 1102
59	59	720 ILCS 570/303.05
60	60	Amends the Physician Assistant Practice Act of 1987. Provides that a physician assistant may prescribe, dispense, order, administer, and procure drugs and medical devices without delegation of authority by a physician. Provides that a physician assistant may practice without a written collaborative agreement. Provides that a physician assistant who files with the Department of Financial and Professional Regulation a notarized attestation of completion of at least 250 hours of continuing education or training and at least 2,000 hours of clinical experience after first attaining national certification shall not require a written collaborative agreement to practice. Makes changes in provisions concerning definitions; physician assistant title; collaboration requirements; written collaborative agreements, prescriptive authority, and physician assistants in hospitals, hospital affiliates, or ambulatory surgical treatment centers; inactive status; limitations; and grounds for disciplinary action. Amends the Illinois Controlled Substances Act to make corresponding changes.
61	61	LRB104 10667 AAS 20746 b LRB104 10667 AAS 20746 b
62	62	LRB104 10667 AAS 20746 b
63	63	A BILL FOR
64	64
65	65
66	66
67	67
68	68
69	69	225 ILCS 95/4 from Ch. 111, par. 4604
70	70	225 ILCS 95/6 from Ch. 111, par. 4606
71	71	225 ILCS 95/7 from Ch. 111, par. 4607
72	72	225 ILCS 95/7.5
73	73	225 ILCS 95/7.7
74	74	225 ILCS 95/7.8 new
75	75	225 ILCS 95/7.9 new
76	76	225 ILCS 95/20 from Ch. 111, par. 4620
77	77	225 ILCS 95/21 from Ch. 111, par. 4621
78	78	720 ILCS 570/102 from Ch. 56 1/2, par. 1102
79	79	720 ILCS 570/303.05
80	80
81	81
82	82
83	83	LRB104 10667 AAS 20746 b
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93	HB2468 LRB104 10667 AAS 20746 b
94	94
95	95
96	96	HB2468- 2 -LRB104 10667 AAS 20746 b HB2468 - 2 - LRB104 10667 AAS 20746 b
97	97	HB2468 - 2 - LRB104 10667 AAS 20746 b
98	98	1 physician assistants as will assure that patients shall
99	99	2 receive quality medical care. Physician assistants shall be
100	100	3 capable of performing a variety of tasks within the specialty
101	101	4 of medical care in collaboration with a physician.
102	102	5 Collaboration with the physician assistant shall not be
103	103	6 construed to necessarily require the personal presence of the
104	104	7 collaborating physician at all times at the place where
105	105	8 services are rendered, as long as there is communication
106	106	9 available for consultation by radio, telephone or
107	107	10 telecommunications within established guidelines as determined
108	108	11 by the physician/physician assistant team. The collaborating
109	109	12 physician may delegate tasks and duties to the physician
110	110	13 assistant. Delegated tasks or duties shall be consistent with
111	111	14 physician assistant education, training, and experience. The
112	112	15 delegated tasks or duties shall be specific to the practice
113	113	16 setting and shall be implemented and reviewed under a written
114	114	17 collaborative agreement established by the physician or
115	115	18 physician/physician assistant team. A physician assistant,
116	116	19 acting as an agent of the physician, shall be permitted to
117	117	20 transmit the collaborating physician's orders as determined by
118	118	21 the institution's by-laws, policies, procedures, or job
119	119	22 description within which the physician/physician assistant
120	120	23 team practices. Physician assistants shall practice only in
121	121	24 accordance with a written collaborative agreement.
122	122	25 Any person who holds an active license or permit issued
123	123	26 pursuant to the Medical Practice Act of 1987 shall have that
124	124
125	125
126	126
127	127
128	128
129	129	HB2468 - 2 - LRB104 10667 AAS 20746 b
130	130
131	131
132	132	HB2468- 3 -LRB104 10667 AAS 20746 b HB2468 - 3 - LRB104 10667 AAS 20746 b
133	133	HB2468 - 3 - LRB104 10667 AAS 20746 b
134	134	1 license automatically placed into inactive status upon
135	135	2 issuance of a physician assistant license. Any person who
136	136	3 holds an active license as a physician assistant who is issued
137	137	4 a license or permit pursuant to the Medical Practice Act of
138	138	5 1987 shall have his or her physician assistant license
139	139	6 automatically placed into inactive status.
140	140	7 3.5. "Physician assistant practice" means the performance
141	141	8 of any legal medical service for which the physician assistant
142	142	9 has been prepared by the physician assistant's education,
143	143	10 training, and experience and is competent to perform as
144	144	11 determined through an employment agreement or the
145	145	12 credentialing and privileging system of a licensed facility.
146	146	13 Medical and surgical services provided by physician assistants
147	147	14 include, but are not limited to:
148	148	15 (A) obtaining and performing comprehensive health
149	149	16 histories and physical examinations;
150	150	17 (B) evaluating, diagnosing, managing, and providing
151	151	18 medical treatment;
152	152	19 (C) ordering, performing, and interpreting diagnostic
153	153	20 studies and therapeutic procedures;
154	154	21 (D) educating patients on health promotion and disease
155	155	22 prevention;
156	156	23 (E) providing consultation upon request;
157	157	24 (F) writing medical orders;
158	158	25 (G) prescribing, dispensing, ordering, administering,
159	159	26 and procuring drugs and medical devices; and
160	160
161	161
162	162
163	163
164	164
165	165	HB2468 - 3 - LRB104 10667 AAS 20746 b
166	166
167	167
168	168	HB2468- 4 -LRB104 10667 AAS 20746 b HB2468 - 4 - LRB104 10667 AAS 20746 b
169	169	HB2468 - 4 - LRB104 10667 AAS 20746 b
170	170	1 (H) assisting in surgery. procedures within the
171	171	2 specialty of the collaborating physician. Physician
172	172	3 assistants shall be capable of performing a variety of
173	173	4 tasks within the specialty of medical care of the
174	174	5 collaborating physician. Collaboration with the physician
175	175	6 assistant shall not be construed to necessarily require
176	176	7 the personal presence of the collaborating physician at
177	177	8 all times at the place where services are rendered, as
178	178	9 long as there is communication available for consultation
179	179	10 by radio, telephone, telecommunications, or electronic
180	180	11 communications. The collaborating physician may delegate
181	181	12 tasks and duties to the physician assistant. Delegated
182	182	13 tasks or duties shall be consistent with physician
183	183	14 assistant education, training, and experience. The
184	184	15 delegated tasks or duties shall be specific to the
185	185	16 practice setting and shall be implemented and reviewed
186	186	17 under a written collaborative agreement established by the
187	187	18 physician or physician/physician assistant team. A
188	188	19 physician assistant shall be permitted to transmit the
189	189	20 collaborating physician's orders as determined by the
190	190	21 institution's bylaws, policies, or procedures or the job
191	191	22 description within which the physician/physician assistant
192	192	23 team practices. Physician assistants shall practice only
193	193	24 in accordance with a written collaborative agreement,
194	194	25 except as provided in Section 7.5 of this Act.
195	195	26 4. "Board" means the Illinois State Medical Board Medical
196	196
197	197
198	198
199	199
200	200
201	201	HB2468 - 4 - LRB104 10667 AAS 20746 b
202	202
203	203
204	204	HB2468- 5 -LRB104 10667 AAS 20746 b HB2468 - 5 - LRB104 10667 AAS 20746 b
205	205	HB2468 - 5 - LRB104 10667 AAS 20746 b
206	206	1 Licensing Board constituted under the Medical Practice Act of
207	207	2 1987.
208	208	3 5. (Blank).
209	209	4 6. "Physician" means a person licensed to practice
210	210	5 medicine in all of its branches under the Medical Practice Act
211	211	6 of 1987.
212	212	7 7. "Collaborating physician" means the physician who,
213	213	8 within his or her specialty and expertise, may delegate a
214	214	9 variety of tasks and procedures to the physician assistant.
215	215	10 Such tasks and procedures shall be delegated in accordance
216	216	11 with a written collaborative agreement when the agreement is
217	217	12 required under this Act.
218	218	13 8. (Blank).
219	219	14 9. "Address of record" means the designated address
220	220	15 recorded by the Department in the applicant's application file
221	221	16 or the licensee's application file or license file, as
222	222	17 maintained by the Department's licensure maintenance unit.
223	223	18 10. "Hospital affiliate" means a corporation, partnership,
224	224	19 joint venture, limited liability company, or similar
225	225	20 organization, other than a hospital, that is devoted primarily
226	226	21 to the provision, management, or support of health care
227	227	22 services and that directly or indirectly controls, is
228	228	23 controlled by, or is under common control of the hospital. For
229	229	24 the purposes of this definition, "control" means having at
230	230	25 least an equal or a majority ownership or membership interest.
231	231	26 A hospital affiliate shall be 100% owned or controlled by any
232	232
233	233
234	234
235	235
236	236
237	237	HB2468 - 5 - LRB104 10667 AAS 20746 b
238	238
239	239
240	240	HB2468- 6 -LRB104 10667 AAS 20746 b HB2468 - 6 - LRB104 10667 AAS 20746 b
241	241	HB2468 - 6 - LRB104 10667 AAS 20746 b
242	242	1 combination of hospitals, their parent corporations, or
243	243	2 physicians licensed to practice medicine in all its branches
244	244	3 in Illinois. "Hospital affiliate" does not include a health
245	245	4 maintenance organization regulated under the Health
246	246	5 Maintenance Organization Act.
247	247	6 11. "Email address of record" means the designated email
248	248	7 address recorded by the Department in the applicant's
249	249	8 application file or the licensee's license file, as maintained
250	250	9 by the Department's licensure maintenance unit.
251	251	10 12. "Federally qualified health center" means a health
252	252	11 center funded under Section 330 of the federal Public Health
253	253	12 Service Act.
254	254	13 (Source: P.A. 102-1117, eff. 1-13-23; 103-65, eff. 1-1-24.)
255	255	14 (225 ILCS 95/6) (from Ch. 111, par. 4606)
256	256	15 (Section scheduled to be repealed on January 1, 2028)
257	257	16 Sec. 6. Physician assistant title.
258	258	17 (a) No physician assistant shall use the title of doctor,
259	259	18 physician, or associate with his or her name or any other term
260	260	19 that would indicate to other persons that he or she is
261	261	20 qualified to engage in the general practice of medicine.
262	262	21 (b) A physician assistant shall verbally identify himself
263	263	22 or herself as a physician assistant, including, when
264	264	23 applicable, specialty certification, to each patient.
265	265	24 (c) Nothing in this Act shall be construed to relieve a
266	266	25 physician assistant of the professional or legal
267	267
268	268
269	269
270	270
271	271
272	272	HB2468 - 6 - LRB104 10667 AAS 20746 b
273	273
274	274
275	275	HB2468- 7 -LRB104 10667 AAS 20746 b HB2468 - 7 - LRB104 10667 AAS 20746 b
276	276	HB2468 - 7 - LRB104 10667 AAS 20746 b
277	277	1 responsibility for the care and treatment of persons attended
278	278	2 by him or her.
279	279	3 (d) (Blank). The collaborating physician shall file with
280	280	4 the Department notice of employment, discharge, or
281	281	5 collaboration with a physician assistant within 60 days of
282	282	6 employment, discharge, or assumption of collaboration with a
283	283	7 physician assistant. Nothing in this Section shall prevent a
284	284	8 physician assistant from beginning his or her employment
285	285	9 before the notice of employment or collaboration has been
286	286	10 filed.
287	287	11 (Source: P.A. 102-735, eff. 1-1-23.)
288	288	12 (225 ILCS 95/7) (from Ch. 111, par. 4607)
289	289	13 (Section scheduled to be repealed on January 1, 2028)
290	290	14 Sec. 7. Collaboration requirements.
291	291	15 (a) A written collaborative agreement is required for all
292	292	16 physician assistants engaged in clinical practice prior to
293	293	17 satisfying the requirements of Section 7.9, except for
294	294	18 physician assistants who practice in a hospital, hospital
295	295	19 affiliate, federally qualified health center, or ambulatory
296	296	20 surgical treatment center as provided in Section 7.7.
297	297	21 (b) (a) A collaborating physician shall determine the
298	298	22 number of physician assistants to collaborate with, provided
299	299	23 the physician is able to provide adequate collaboration as
300	300	24 outlined in the written collaborative agreement required under
301	301	25 Section 7.5 of this Act and consideration is given to the
302	302
303	303
304	304
305	305
306	306
307	307	HB2468 - 7 - LRB104 10667 AAS 20746 b
308	308
309	309
310	310	HB2468- 8 -LRB104 10667 AAS 20746 b HB2468 - 8 - LRB104 10667 AAS 20746 b
311	311	HB2468 - 8 - LRB104 10667 AAS 20746 b
312	312	1 nature of the physician's practice, complexity of the patient
313	313	2 population, and the experience of each physician assistant. A
314	314	3 collaborating physician may collaborate with a maximum of 7
315	315	4 full-time equivalent physician assistants as described in
316	316	5 Section 54.5 of the Medical Practice Act of 1987. As used in
317	317	6 this Section, "full-time equivalent" means the equivalent of
318	318	7 40 hours per week per individual. Physicians and physician
319	319	8 assistants who work in a hospital, hospital affiliate,
320	320	9 federally qualified health center, or ambulatory surgical
321	321	10 treatment center as defined by Section 7.7 of this Act are
322	322	11 exempt from the collaborative ratio restriction requirements
323	323	12 of this Section. A physician assistant shall be able to hold
324	324	13 more than one professional position. A collaborating physician
325	325	14 shall file a notice of collaboration of each physician
326	326	15 assistant according to the rules of the Department.
327	327	16 (c) Physician assistants shall collaborate only with
328	328	17 physicians as defined in this Act who are engaged in clinical
329	329	18 practice, or in clinical practice in public health or other
330	330	19 community health facilities.
331	331	20 (d) Nothing in this Act shall be construed to limit the
332	332	21 delegation of tasks or duties by a physician to a nurse or
333	333	22 other appropriately trained personnel.
334	334	23 (e) Nothing in this Act shall be construed to prohibit the
335	335	24 employment of physician assistants by a hospital, nursing home
336	336	25 or other health care facility where such physician assistants
337	337	26 function with under a collaborating physician.
338	338
339	339
340	340
341	341
342	342
343	343	HB2468 - 8 - LRB104 10667 AAS 20746 b
344	344
345	345
346	346	HB2468- 9 -LRB104 10667 AAS 20746 b HB2468 - 9 - LRB104 10667 AAS 20746 b
347	347	HB2468 - 9 - LRB104 10667 AAS 20746 b
348	348	1 (f) A physician assistant may be employed by a practice
349	349	2 group or other entity employing multiple physicians at one or
350	350	3 more locations. In that case, one of the physicians practicing
351	351	4 at a location shall be designated the collaborating physician.
352	352	5 The other physicians with that practice group or other entity
353	353	6 who practice in the same general type of practice or specialty
354	354	7 as the collaborating physician may collaborate with the
355	355	8 physician assistant with respect to their patients.
356	356	9 (g) (b) A physician assistant licensed in this State, or
357	357	10 licensed or authorized to practice in any other U.S.
358	358	11 jurisdiction or credentialed by his or her federal employer as
359	359	12 a physician assistant, who is responding to a need for medical
360	360	13 care created by an emergency or by a state or local disaster
361	361	14 may render such care that the physician assistant is able to
362	362	15 provide without collaboration as it is defined in this Section
363	363	16 or with such collaboration as is available.
364	364	17 (h) Any physician who collaborates with a physician
365	365	18 assistant providing medical care in response to such an
366	366	19 emergency or state or local disaster shall not be required to
367	367	20 meet the requirements set forth in this Section for a
368	368	21 collaborating physician.
369	369	22 (Source: P.A. 103-65, eff. 1-1-24.)
370	370	23 (225 ILCS 95/7.5)
371	371	24 (Section scheduled to be repealed on January 1, 2028)
372	372	25 Sec. 7.5. Written collaborative agreements; prescriptive
373	373
374	374
375	375
376	376
377	377
378	378	HB2468 - 9 - LRB104 10667 AAS 20746 b
379	379
380	380
381	381	HB2468- 10 -LRB104 10667 AAS 20746 b HB2468 - 10 - LRB104 10667 AAS 20746 b
382	382	HB2468 - 10 - LRB104 10667 AAS 20746 b
383	383	1 authority.
384	384	2 (a) A written collaborative agreement is required for all
385	385	3 physician assistants to practice in the State, except as
386	386	4 provided in Sections Section 7.7 and 7.9 of this Act. When a
387	387	5 written collaborative agreement is required under this Act,
388	388	6 the following shall apply:
389	389	7 (1) A written collaborative agreement shall describe
390	390	8 the working relationship of the physician assistant with
391	391	9 the collaborating physician and shall describe the
392	392	10 categories of care, treatment, or procedures to be
393	393	11 provided by the physician assistant. The written
394	394	12 collaborative agreement shall promote the exercise of
395	395	13 professional judgment by the physician assistant
396	396	14 commensurate with his or her education and experience. The
397	397	15 services to be provided by the physician assistant shall
398	398	16 be services that the collaborating physician is authorized
399	399	17 to and generally provides to his or her patients in the
400	400	18 normal course of his or her clinical medical practice. The
401	401	19 written collaborative agreement need not describe the
402	402	20 exact steps that a physician assistant must take with
403	403	21 respect to each specific condition, disease, or symptom
404	404	22 but must specify which authorized procedures require the
405	405	23 presence of the collaborating physician as the procedures
406	406	24 are being performed. The relationship under a written
407	407	25 collaborative agreement shall not be construed to require
408	408	26 the personal presence of a physician at the place where
409	409
410	410
411	411
412	412
413	413
414	414	HB2468 - 10 - LRB104 10667 AAS 20746 b
415	415
416	416
417	417	HB2468- 11 -LRB104 10667 AAS 20746 b HB2468 - 11 - LRB104 10667 AAS 20746 b
418	418	HB2468 - 11 - LRB104 10667 AAS 20746 b
419	419	1 services are rendered. Methods of communication shall be
420	420	2 available for consultation with the collaborating
421	421	3 physician in person or by telecommunications or electronic
422	422	4 communications as set forth in the written collaborative
423	423	5 agreement. For the purposes of this Act, "generally
424	424	6 provides to his or her patients in the normal course of his
425	425	7 or her clinical medical practice" means services, not
426	426	8 specific tasks or duties, the collaborating physician
427	427	9 routinely provides individually or through delegation to
428	428	10 other persons so that the physician has the experience and
429	429	11 ability to collaborate and provide consultation.
430	430	12 (2) (Blank). The written collaborative agreement shall
431	431	13 be adequate if a physician does each of the following:
432	432	14 (A) Participates in the joint formulation and
433	433	15 joint approval of orders or guidelines with the
434	434	16 physician assistant and he or she periodically reviews
435	435	17 such orders and the services provided patients under
436	436	18 such orders in accordance with accepted standards of
437	437	19 medical practice and physician assistant practice.
438	438	20 (B) Provides consultation at least once a month.
439	439	21 (3) A copy of the signed, written collaborative
440	440	22 agreement must be available to the Department upon request
441	441	23 from both the physician assistant and the collaborating
442	442	24 physician.
443	443	25 (4) A physician assistant shall inform each
444	444	26 collaborating physician of all written collaborative
445	445
446	446
447	447
448	448
449	449
450	450	HB2468 - 11 - LRB104 10667 AAS 20746 b
451	451
452	452
453	453	HB2468- 12 -LRB104 10667 AAS 20746 b HB2468 - 12 - LRB104 10667 AAS 20746 b
454	454	HB2468 - 12 - LRB104 10667 AAS 20746 b
455	455	1 agreements he or she has signed and provide a copy of these
456	456	2 to any collaborating physician upon request.
457	457	3 (b) To prescribe Schedule II, III, IV, or V controlled
458	458	4 substances under this Section, a physician assistant must
459	459	5 obtain a mid-level practitioner controlled substances license.
460	460	6 A collaborating physician may, but is not required to,
461	461	7 delegate prescriptive authority to a physician assistant as
462	462	8 part of a written collaborative agreement. This authority may,
463	463	9 but is not required to, include prescription of, selection of,
464	464	10 orders for, administration of, storage of, acceptance of
465	465	11 samples of, and dispensing medical devices, over-the-counter
466	466	12 medications, legend drugs, medical gases, and controlled
467	467	13 substances categorized as Schedule II through V controlled
468	468	14 substances, as defined in Article II of the Illinois
469	469	15 Controlled Substances Act, and other preparations, including,
470	470	16 but not limited to, botanical and herbal remedies. The
471	471	17 collaborating physician must have a valid, current Illinois
472	472	18 controlled substance license and federal registration with the
473	473	19 Drug Enforcement Administration to delegate the authority to
474	474	20 prescribe controlled substances.
475	475	21 (1) To prescribe Schedule II, III, IV, or V controlled
476	476	22 substances under this Section, a physician assistant must
477	477	23 obtain a mid-level practitioner controlled substances
478	478	24 license. Medication orders issued by a physician assistant
479	479	25 shall be reviewed periodically by the collaborating
480	480	26 physician.
481	481
482	482
483	483
484	484
485	485
486	486	HB2468 - 12 - LRB104 10667 AAS 20746 b
487	487
488	488
489	489	HB2468- 13 -LRB104 10667 AAS 20746 b HB2468 - 13 - LRB104 10667 AAS 20746 b
490	490	HB2468 - 13 - LRB104 10667 AAS 20746 b
491	491	1 (2) The collaborating physician shall file with the
492	492	2 Department notice of delegation of prescriptive authority
493	493	3 to a physician assistant and termination of delegation,
494	494	4 specifying the authority delegated or terminated. Upon
495	495	5 receipt of this notice delegating authority to prescribe
496	496	6 controlled substances, the physician assistant shall be
497	497	7 eligible to register for a mid-level practitioner
498	498	8 controlled substances license under Section 303.05 of the
499	499	9 Illinois Controlled Substances Act. Nothing in this Act
500	500	10 shall be construed to limit the delegation of tasks or
501	501	11 duties by the collaborating physician to a nurse or other
502	502	12 appropriately trained persons in accordance with Section
503	503	13 54.2 of the Medical Practice Act of 1987.
504	504	14 (3) In addition to the requirements of this subsection
505	505	15 (b), a collaborating physician may, but is not required
506	506	16 to, delegate authority to a physician assistant to
507	507	17 prescribe Schedule II controlled substances, if all of the
508	508	18 following conditions apply:
509	509	19 (A) Specific Schedule II controlled substances by
510	510	20 oral dosage or topical or transdermal application may
511	511	21 be delegated, provided that the delegated Schedule II
512	512	22 controlled substances are routinely prescribed by the
513	513	23 collaborating physician. This delegation must identify
514	514	24 the specific Schedule II controlled substances by
515	515	25 either brand name or generic name. Schedule II
516	516	26 controlled substances to be delivered by injection or
517	517
518	518
519	519
520	520
521	521
522	522	HB2468 - 13 - LRB104 10667 AAS 20746 b
523	523
524	524
525	525	HB2468- 14 -LRB104 10667 AAS 20746 b HB2468 - 14 - LRB104 10667 AAS 20746 b
526	526	HB2468 - 14 - LRB104 10667 AAS 20746 b
527	527	1 other route of administration may not be delegated.
528	528	2 (B) (Blank).
529	529	3 (C) Any prescription must be limited to no more
530	530	4 than a 30-day supply, with any continuation authorized
531	531	5 only after prior approval of the collaborating
532	532	6 physician.
533	533	7 (D) The physician assistant must discuss the
534	534	8 condition of any patients for whom a controlled
535	535	9 substance is prescribed monthly with the collaborating
536	536	10 physician.
537	537	11 (E) The physician assistant meets the education
538	538	12 requirements of Section 303.05 of the Illinois
539	539	13 Controlled Substances Act.
540	540	14 (c) Nothing in this Act shall be construed to limit the
541	541	15 delegation of tasks or duties by a physician to a licensed
542	542	16 practical nurse, a registered professional nurse, or other
543	543	17 persons. Nothing in this Act shall be construed to limit the
544	544	18 method of delegation that may be authorized by any means,
545	545	19 including, but not limited to, oral, written, electronic,
546	546	20 standing orders, protocols, guidelines, or verbal orders.
547	547	21 Nothing in this Act shall be construed to authorize a
548	548	22 physician assistant to provide health care services required
549	549	23 by law or rule to be performed by a physician. Nothing in this
550	550	24 Act shall be construed to authorize the delegation or
551	551	25 performance of operative surgery. Nothing in this Section
552	552	26 shall be construed to preclude a physician assistant from
553	553
554	554
555	555
556	556
557	557
558	558	HB2468 - 14 - LRB104 10667 AAS 20746 b
559	559
560	560
561	561	HB2468- 15 -LRB104 10667 AAS 20746 b HB2468 - 15 - LRB104 10667 AAS 20746 b
562	562	HB2468 - 15 - LRB104 10667 AAS 20746 b
563	563	1 assisting in surgery.
564	564	2 (c-5) Nothing in this Section shall be construed to apply
565	565	3 to any medication authority, including Schedule II controlled
566	566	4 substances of a licensed physician assistant for care provided
567	567	5 in a hospital, hospital affiliate, federally qualified health
568	568	6 center, or ambulatory surgical treatment center pursuant to
569	569	7 Section 7.7 of this Act, or to a physician assistant
570	570	8 satisfying the requirements of Section 7.9 of this Act.
571	571	9 (d) (Blank).
572	572	10 (e) Nothing in this Section shall be construed to prohibit
573	573	11 generic substitution.
574	574	12 (f) Delegation of prescriptive authority by a physician is
575	575	13 not required under this Section.
576	576	14 (Source: P.A. 102-558, eff. 8-20-21; 103-65, eff. 1-1-24;
577	577	15 103-605, eff. 7-1-24.)
578	578	16 (225 ILCS 95/7.7)
579	579	17 (Section scheduled to be repealed on January 1, 2028)
580	580	18 Sec. 7.7. Physician assistants in hospitals, hospital
581	581	19 affiliates, federally qualified health centers, or ambulatory
582	582	20 surgical treatment centers.
583	583	21 (a) A physician assistant may provide services in a
584	584	22 hospital as defined in the Hospital Licensing Act, a hospital
585	585	23 affiliate as defined in the University of Illinois Hospital
586	586	24 Act, a federally qualified health center, or a licensed
587	587	25 ambulatory surgical treatment center as defined in the
588	588
589	589
590	590
591	591
592	592
593	593	HB2468 - 15 - LRB104 10667 AAS 20746 b
594	594
595	595
596	596	HB2468- 16 -LRB104 10667 AAS 20746 b HB2468 - 16 - LRB104 10667 AAS 20746 b
597	597	HB2468 - 16 - LRB104 10667 AAS 20746 b
598	598	1 Ambulatory Surgical Treatment Center Act without a written
599	599	2 collaborative agreement pursuant to Section 7.5 of this Act
600	600	3 only in accordance with this Section. A physician assistant
601	601	4 must possess clinical privileges recommended by (i) the
602	602	5 hospital medical staff and granted by the hospital, (ii) the
603	603	6 physician committee and federally qualified health center, or
604	604	7 (iii) the consulting medical staff committee and ambulatory
605	605	8 surgical treatment center in order to provide services. The
606	606	9 medical staff, physician committee, or consulting medical
607	607	10 staff committee shall periodically review the services of
608	608	11 physician assistants granted clinical privileges, including
609	609	12 any care provided in a hospital affiliate or federally
610	610	13 qualified health center. A physician assistant practicing
611	611	14 under this Section may prescribe, select, order, and
612	612	15 administer medications, including controlled substances.
613	613	16 Authority may also be granted when recommended by the hospital
614	614	17 medical staff and granted by the hospital, recommended by the
615	615	18 physician committee and granted by the federally qualified
616	616	19 health center, or recommended by the consulting medical staff
617	617	20 committee and ambulatory surgical treatment center to
618	618	21 individual physician assistants to select, order, and
619	619	22 administer medications, including controlled substances, to
620	620	23 provide delineated care. In a hospital, hospital affiliate,
621	621	24 federally qualified health center, or ambulatory surgical
622	622	25 treatment center, the attending physician shall determine a
623	623	26 physician assistant's role in providing care for his or her
624	624
625	625
626	626
627	627
628	628
629	629	HB2468 - 16 - LRB104 10667 AAS 20746 b
630	630
631	631
632	632	HB2468- 17 -LRB104 10667 AAS 20746 b HB2468 - 17 - LRB104 10667 AAS 20746 b
633	633	HB2468 - 17 - LRB104 10667 AAS 20746 b
634	634	1 patients, except as otherwise provided in the medical staff
635	635	2 bylaws or consulting committee policies.
636	636	3 (a-5) Physician assistants practicing in a hospital
637	637	4 affiliate or a federally qualified health center may be, but
638	638	5 are not required to be, granted authority to prescribe
639	639	6 Schedule II through V controlled substances when such
640	640	7 authority is recommended by the appropriate physician
641	641	8 committee of the hospital affiliate and granted by the
642	642	9 hospital affiliate or recommended by the physician committee
643	643	10 of the federally qualified health center and granted by the
644	644	11 federally qualified health center. This authority may, but is
645	645	12 not required to, include prescription of, selection of, orders
646	646	13 for, administration of, storage of, acceptance of samples of,
647	647	14 and dispensing over-the-counter medications, legend drugs,
648	648	15 medical gases, and controlled substances categorized as
649	649	16 Schedule II through V controlled substances, as defined in
650	650	17 Article II of the Illinois Controlled Substances Act, and
651	651	18 other preparations, including, but not limited to, botanical
652	652	19 and herbal remedies.
653	653	20 To prescribe controlled substances under this subsection
654	654	21 (a-5), a physician assistant must obtain a mid-level
655	655	22 practitioner controlled substance license. Medication orders
656	656	23 shall be reviewed periodically by the appropriate hospital
657	657	24 affiliate physicians committee or its physician designee or by
658	658	25 the physician committee of a federally qualified health
659	659	26 center.
660	660
661	661
662	662
663	663
664	664
665	665	HB2468 - 17 - LRB104 10667 AAS 20746 b
666	666
667	667
668	668	HB2468- 18 -LRB104 10667 AAS 20746 b HB2468 - 18 - LRB104 10667 AAS 20746 b
669	669	HB2468 - 18 - LRB104 10667 AAS 20746 b
670	670	1 The hospital affiliate or federally qualified health
671	671	2 center shall file with the Department notice of a grant of
672	672	3 prescriptive authority consistent with this subsection (a-5)
673	673	4 and termination of such a grant of authority in accordance
674	674	5 with rules of the Department. Upon receipt of this notice of
675	675	6 grant of authority to prescribe any Schedule II through V
676	676	7 controlled substances, the licensed physician assistant may
677	677	8 register for a mid-level practitioner controlled substance
678	678	9 license under Section 303.05 of the Illinois Controlled
679	679	10 Substances Act.
680	680	11 In addition, a hospital affiliate or a federally qualified
681	681	12 health center may, but is not required to, grant authority to a
682	682	13 physician assistant to prescribe any Schedule II controlled
683	683	14 substances if all of the following conditions apply:
684	684	15 (1) specific Schedule II controlled substances by oral
685	685	16 dosage or topical or transdermal application may be
686	686	17 designated, provided that the designated Schedule II
687	687	18 controlled substances are routinely prescribed by
688	688	19 physician assistants in their area of certification; this
689	689	20 grant of authority must identify the specific Schedule II
690	690	21 controlled substances by either brand name or generic
691	691	22 name; authority to prescribe or dispense Schedule II
692	692	23 controlled substances to be delivered by injection or
693	693	24 other route of administration may not be granted;
694	694	25 (2) any grant of authority must be controlled
695	695	26 substances limited to the practice of the physician
696	696
697	697
698	698
699	699
700	700
701	701	HB2468 - 18 - LRB104 10667 AAS 20746 b
702	702
703	703
704	704	HB2468- 19 -LRB104 10667 AAS 20746 b HB2468 - 19 - LRB104 10667 AAS 20746 b
705	705	HB2468 - 19 - LRB104 10667 AAS 20746 b
706	706	1 assistant;
707	707	2 (3) any prescription must be limited to no more than a
708	708	3 30-day supply;
709	709	4 (4) the physician assistant must discuss the condition
710	710	5 of any patients for whom a controlled substance is
711	711	6 prescribed monthly with the appropriate physician
712	712	7 committee of the hospital affiliate or its physician
713	713	8 designee, or the physician committee of a federally
714	714	9 qualified health center; and
715	715	10 (5) the physician assistant must meet the education
716	716	11 requirements of Section 303.05 of the Illinois Controlled
717	717	12 Substances Act.
718	718	13 (b) A physician assistant granted authority to order
719	719	14 medications including controlled substances may complete
720	720	15 discharge prescriptions provided the prescription is in the
721	721	16 name of the physician assistant and the attending or
722	722	17 discharging physician.
723	723	18 (c) Physician assistants practicing in a hospital,
724	724	19 hospital affiliate, federally qualified health center, or an
725	725	20 ambulatory surgical treatment center are not required to
726	726	21 obtain a mid-level controlled substance license to order
727	727	22 controlled substances under Section 303.05 of the Illinois
728	728	23 Controlled Substances Act.
729	729	24 (d) Delegation of prescriptive authority by a physician is
730	730	25 not required under this Section.
731	731	26 (Source: P.A. 103-65, eff. 1-1-24.)
732	732
733	733
734	734
735	735
736	736
737	737	HB2468 - 19 - LRB104 10667 AAS 20746 b
738	738
739	739
740	740	HB2468- 20 -LRB104 10667 AAS 20746 b HB2468 - 20 - LRB104 10667 AAS 20746 b
741	741	HB2468 - 20 - LRB104 10667 AAS 20746 b
742	742	1 (225 ILCS 95/7.8 new)
743	743	2 Sec. 7.8. Prescriptive authority. A physician assistant
744	744	3 may prescribe, dispense, order, administer, and procure drugs
745	745	4 and medical devices without delegation of authority by a
746	746	5 physician. The prescriptive authority may include prescribing
747	747	6 Schedule II, III, IV, and V controlled substances. To
748	748	7 prescribe Schedule II, III, IV, or V controlled substances
749	749	8 under this Act, a physician assistant must obtain a mid-level
750	750	9 practitioner controlled substances license. When a written
751	751	10 collaborative agreement is required under this Act, delegation
752	752	11 of prescriptive authority by a physician is not required.
753	753	12 (225 ILCS 95/7.9 new)
754	754	13 Sec. 7.9. Optimal practice.
755	755	14 (a) A physician assistant may practice without a written
756	756	15 collaborative agreement as described in this Section.
757	757	16 (b) A physician assistant who files with the Department a
758	758	17 notarized attestation of completion of at least 250 hours of
759	759	18 continuing education or training and at least 2,000 hours of
760	760	19 clinical experience after first attaining national
761	761	20 certification shall not require a written collaborative
762	762	21 agreement to practice. Documentation of successful completion
763	763	22 shall be provided to the Department upon request.
764	764	23 (c) The scope of practice of a physician assistant with
765	765	24 optimal practice includes:
766	766
767	767
768	768
769	769
770	770
771	771	HB2468 - 20 - LRB104 10667 AAS 20746 b
772	772
773	773
774	774	HB2468- 21 -LRB104 10667 AAS 20746 b HB2468 - 21 - LRB104 10667 AAS 20746 b
775	775	HB2468 - 21 - LRB104 10667 AAS 20746 b
776	776	1 (1) all matters defined as physician assistant
777	777	2 practice;
778	778	3 (2) practicing without a written collaborative
779	779	4 agreement in all practice settings consistent with this
780	780	5 Act;
781	781	6 (3) authority to prescribe both legend drugs and
782	782	7 Schedule II through V controlled substances, including
783	783	8 prescription of, selection of, orders for, administration
784	784	9 of, storage of, acceptance of, samples of, and dispensing
785	785	10 over-the-counter medications, legend drugs, and controlled
786	786	11 substances categorized as Schedule II through V controlled
787	787	12 substances, as defined in Article II of the Illinois
788	788	13 Controlled Substances Act, and other preparations,
789	789	14 including, but not limited to, botanical and herbal
790	790	15 remedies; and
791	791	16 (4) authority to obtain an Illinois controlled
792	792	17 substance license and a federal Drug Enforcement
793	793	18 Administration number.
794	794	19 The scope of practice of a physician assistant does not
795	795	20 include operative surgery. Nothing in this Section shall be
796	796	21 construed to preclude a physician assistant from assisting in
797	797	22 surgery or performing other procedures as privileged by the
798	798	23 physician assistant's employer.
799	799	24 (d) The Department may adopt rules necessary to administer
800	800	25 this Section, including, but not limited to, requiring the
801	801	26 completion of forms and the payment of fees.
802	802
803	803
804	804
805	805
806	806
807	807	HB2468 - 21 - LRB104 10667 AAS 20746 b
808	808
809	809
810	810	HB2468- 22 -LRB104 10667 AAS 20746 b HB2468 - 22 - LRB104 10667 AAS 20746 b
811	811	HB2468 - 22 - LRB104 10667 AAS 20746 b
812	812	1 (e) Nothing in this Section shall be construed to prohibit
813	813	2 a physician assistant's employer from requiring a physician
814	814	3 assistant who satisfies the qualifications of subsection (b)
815	815	4 to practice with a written collaborative agreement.
816	816	5 (f) Nothing in this Act shall be construed to authorize a
817	817	6 physician assistant with optimal practice authority to provide
818	818	7 health care services required by law or rule to be performed by
819	819	8 a physician.
820	820	9 (225 ILCS 95/20) (from Ch. 111, par. 4620)
821	821	10 (Section scheduled to be repealed on January 1, 2028)
822	822	11 Sec. 20. Limitations.
823	823	12 (a) No corporation, which stated purpose includes, or
824	824	13 which practices, or which holds itself out as available to
825	825	14 practice as a physician assistant or to practice any of the
826	826	15 functions described in Section 4 of this Act, shall be issued a
827	827	16 license by the Department, nor shall the Secretary of State
828	828	17 approve or accept articles of incorporation for such a
829	829	18 corporation.
830	830	19 (b) Pursuant to subparagraph (a) of paragraph (2) of
831	831	20 Section 3.6 of the Professional Service Corporation Act and
832	832	21 Section 2 of the Medical Corporation Act, a person licensed
833	833	22 under this Act may not own a corporation for the purposes of
834	834	23 practicing medicine.
835	835	24 (c) Pursuant to paragraph (2) of subsection (a) of Section
836	836	25 13 of the Professional Limited Liability Company Act, a person
837	837
838	838
839	839
840	840
841	841
842	842	HB2468 - 22 - LRB104 10667 AAS 20746 b
843	843
844	844
845	845	HB2468- 23 -LRB104 10667 AAS 20746 b HB2468 - 23 - LRB104 10667 AAS 20746 b
846	846	HB2468 - 23 - LRB104 10667 AAS 20746 b
847	847	1 licensed under this Act may not own a professional limited
848	848	2 liability company for the purposes of practicing medicine.
849	849	3 (Source: P.A. 85-981.)
850	850	4 (225 ILCS 95/21) (from Ch. 111, par. 4621)
851	851	5 (Section scheduled to be repealed on January 1, 2028)
852	852	6 Sec. 21. Grounds for disciplinary action.
853	853	7 (a) The Department may refuse to issue or to renew, or may
854	854	8 revoke, suspend, place on probation, reprimand, or take other
855	855	9 disciplinary or non-disciplinary action with regard to any
856	856	10 license issued under this Act as the Department may deem
857	857	11 proper, including the issuance of fines not to exceed $10,000
858	858	12 for each violation, for any one or combination of the
859	859	13 following causes:
860	860	14 (1) Material misstatement in furnishing information to
861	861	15 the Department.
862	862	16 (2) Violations of this Act, or the rules adopted under
863	863	17 this Act.
864	864	18 (3) Conviction by plea of guilty or nolo contendere,
865	865	19 finding of guilt, jury verdict, or entry of judgment or
866	866	20 sentencing, including, but not limited to, convictions,
867	867	21 preceding sentences of supervision, conditional discharge,
868	868	22 or first offender probation, under the laws of any
869	869	23 jurisdiction of the United States that is: (i) a felony;
870	870	24 or (ii) a misdemeanor, an essential element of which is
871	871	25 dishonesty, or that is directly related to the practice of
872	872
873	873
874	874
875	875
876	876
877	877	HB2468 - 23 - LRB104 10667 AAS 20746 b
878	878
879	879
880	880	HB2468- 24 -LRB104 10667 AAS 20746 b HB2468 - 24 - LRB104 10667 AAS 20746 b
881	881	HB2468 - 24 - LRB104 10667 AAS 20746 b
882	882	1 the profession.
883	883	2 (4) Making any misrepresentation for the purpose of
884	884	3 obtaining licenses.
885	885	4 (5) Professional incompetence.
886	886	5 (6) Aiding or assisting another person in violating
887	887	6 any provision of this Act or its rules.
888	888	7 (7) Failing, within 60 days, to provide information in
889	889	8 response to a written request made by the Department.
890	890	9 (8) Engaging in dishonorable, unethical, or
891	891	10 unprofessional conduct, as defined by rule, of a character
892	892	11 likely to deceive, defraud, or harm the public.
893	893	12 (9) Habitual or excessive use or addiction to alcohol,
894	894	13 narcotics, stimulants, or any other chemical agent or drug
895	895	14 that results in a physician assistant's inability to
896	896	15 practice with reasonable judgment, skill, or safety.
897	897	16 (10) Discipline by another U.S. jurisdiction or
898	898	17 foreign nation, if at least one of the grounds for
899	899	18 discipline is the same or substantially equivalent to
900	900	19 those set forth in this Section.
901	901	20 (11) Directly or indirectly giving to or receiving
902	902	21 from any person, firm, corporation, partnership, or
903	903	22 association any fee, commission, rebate or other form of
904	904	23 compensation for any professional services not actually or
905	905	24 personally rendered. Nothing in this paragraph (11)
906	906	25 affects any bona fide independent contractor or employment
907	907	26 arrangements, which may include provisions for
908	908
909	909
910	910
911	911
912	912
913	913	HB2468 - 24 - LRB104 10667 AAS 20746 b
914	914
915	915
916	916	HB2468- 25 -LRB104 10667 AAS 20746 b HB2468 - 25 - LRB104 10667 AAS 20746 b
917	917	HB2468 - 25 - LRB104 10667 AAS 20746 b
918	918	1 compensation, health insurance, pension, or other
919	919	2 employment benefits, with persons or entities authorized
920	920	3 under this Act for the provision of services within the
921	921	4 scope of the licensee's practice under this Act.
922	922	5 (12) A finding by the Board that the licensee, after
923	923	6 having his or her license placed on probationary status,
924	924	7 has violated the terms of probation.
925	925	8 (13) Abandonment of a patient.
926	926	9 (14) Willfully making or filing false records or
927	927	10 reports in his or her practice, including, but not limited
928	928	11 to, false records filed with State agencies or
929	929	12 departments.
930	930	13 (15) Willfully failing to report an instance of
931	931	14 suspected child abuse or neglect as required by the Abused
932	932	15 and Neglected Child Reporting Act.
933	933	16 (16) Physical illness, or mental illness or impairment
934	934	17 that results in the inability to practice the profession
935	935	18 with reasonable judgment, skill, or safety, including, but
936	936	19 not limited to, deterioration through the aging process or
937	937	20 loss of motor skill.
938	938	21 (17) Being named as a perpetrator in an indicated
939	939	22 report by the Department of Children and Family Services
940	940	23 under the Abused and Neglected Child Reporting Act, and
941	941	24 upon proof by clear and convincing evidence that the
942	942	25 licensee has caused a child to be an abused child or
943	943	26 neglected child as defined in the Abused and Neglected
944	944
945	945
946	946
947	947
948	948
949	949	HB2468 - 25 - LRB104 10667 AAS 20746 b
950	950
951	951
952	952	HB2468- 26 -LRB104 10667 AAS 20746 b HB2468 - 26 - LRB104 10667 AAS 20746 b
953	953	HB2468 - 26 - LRB104 10667 AAS 20746 b
954	954	1 Child Reporting Act.
955	955	2 (18) (Blank).
956	956	3 (19) Gross negligence resulting in permanent injury or
957	957	4 death of a patient.
958	958	5 (20) Employment of fraud, deception or any unlawful
959	959	6 means in applying for or securing a license as a physician
960	960	7 assistant.
961	961	8 (21) Exceeding the authority delegated to him or her
962	962	9 by his or her collaborating physician in a written
963	963	10 collaborative agreement, when the agreement is required
964	964	11 under this Act.
965	965	12 (22) Immoral conduct in the commission of any act,
966	966	13 such as sexual abuse, sexual misconduct, or sexual
967	967	14 exploitation related to the licensee's practice.
968	968	15 (23) Violation of the Health Care Worker Self-Referral
969	969	16 Act.
970	970	17 (24) Practicing under a false or assumed name, except
971	971	18 as provided by law.
972	972	19 (25) Making a false or misleading statement regarding
973	973	20 his or her skill or the efficacy or value of the medicine,
974	974	21 treatment, or remedy prescribed by him or her in the
975	975	22 course of treatment.
976	976	23 (26) Allowing another person to use his or her license
977	977	24 to practice.
978	978	25 (27) Prescribing, selling, administering,
979	979	26 distributing, giving, or self-administering a drug
980	980
981	981
982	982
983	983
984	984
985	985	HB2468 - 26 - LRB104 10667 AAS 20746 b
986	986
987	987
988	988	HB2468- 27 -LRB104 10667 AAS 20746 b HB2468 - 27 - LRB104 10667 AAS 20746 b
989	989	HB2468 - 27 - LRB104 10667 AAS 20746 b
990	990	1 classified as a controlled substance for other than
991	991	2 medically accepted therapeutic purposes.
992	992	3 (28) Promotion of the sale of drugs, devices,
993	993	4 appliances, or goods provided for a patient in a manner to
994	994	5 exploit the patient for financial gain.
995	995	6 (29) A pattern of practice or other behavior that
996	996	7 demonstrates incapacity or incompetence to practice under
997	997	8 this Act.
998	998	9 (30) Violating State or federal laws or regulations
999	999	10 relating to controlled substances or other legend drugs or
1000	1000	11 ephedra as defined in the Ephedra Prohibition Act.
1001	1001	12 (31) (Blank). Exceeding the prescriptive authority
1002	1002	13 delegated by the collaborating physician or violating the
1003	1003	14 written collaborative agreement delegating that authority.
1004	1004	15 (32) (Blank). Practicing without providing to the
1005	1005	16 Department a notice of collaboration or delegation of
1006	1006	17 prescriptive authority.
1007	1007	18 (33) Failure to establish and maintain records of
1008	1008	19 patient care and treatment as required by law.
1009	1009	20 (34) Attempting to subvert or cheat on the examination
1010	1010	21 of the National Commission on Certification of Physician
1011	1011	22 Assistants or its successor agency.
1012	1012	23 (35) Willfully or negligently violating the
1013	1013	24 confidentiality between physician assistant and patient,
1014	1014	25 except as required by law.
1015	1015	26 (36) Willfully failing to report an instance of
1016	1016
1017	1017
1018	1018
1019	1019
1020	1020
1021	1021	HB2468 - 27 - LRB104 10667 AAS 20746 b
1022	1022
1023	1023
1024	1024	HB2468- 28 -LRB104 10667 AAS 20746 b HB2468 - 28 - LRB104 10667 AAS 20746 b
1025	1025	HB2468 - 28 - LRB104 10667 AAS 20746 b
1026	1026	1 suspected abuse, neglect, financial exploitation, or
1027	1027	2 self-neglect of an eligible adult as defined in and
1028	1028	3 required by the Adult Protective Services Act.
1029	1029	4 (37) Being named as an abuser in a verified report by
1030	1030	5 the Department on Aging under the Adult Protective
1031	1031	6 Services Act and upon proof by clear and convincing
1032	1032	7 evidence that the licensee abused, neglected, or
1033	1033	8 financially exploited an eligible adult as defined in the
1034	1034	9 Adult Protective Services Act.
1035	1035	10 (38) Failure to report to the Department an adverse
1036	1036	11 final action taken against him or her by another licensing
1037	1037	12 jurisdiction of the United States or a foreign state or
1038	1038	13 country, a peer review body, a health care institution, a
1039	1039	14 professional society or association, a governmental
1040	1040	15 agency, a law enforcement agency, or a court acts or
1041	1041	16 conduct similar to acts or conduct that would constitute
1042	1042	17 grounds for action under this Section.
1043	1043	18 (39) Failure to provide copies of records of patient
1044	1044	19 care or treatment, except as required by law.
1045	1045	20 (40) (Blank). Entering into an excessive number of
1046	1046	21 written collaborative agreements with licensed physicians
1047	1047	22 resulting in an inability to adequately collaborate.
1048	1048	23 (41) (Blank). Repeated failure to adequately
1049	1049	24 collaborate with a collaborating physician.
1050	1050	25 (42) Violating the Compassionate Use of Medical
1051	1051	26 Cannabis Program Act.
1052	1052
1053	1053
1054	1054
1055	1055
1056	1056
1057	1057	HB2468 - 28 - LRB104 10667 AAS 20746 b
1058	1058
1059	1059
1060	1060	HB2468- 29 -LRB104 10667 AAS 20746 b HB2468 - 29 - LRB104 10667 AAS 20746 b
1061	1061	HB2468 - 29 - LRB104 10667 AAS 20746 b
1062	1062	1 (b) The Department may, without a hearing, refuse to issue
1063	1063	2 or renew or may suspend the license of any person who fails to
1064	1064	3 file a return, or to pay the tax, penalty or interest shown in
1065	1065	4 a filed return, or to pay any final assessment of the tax,
1066	1066	5 penalty, or interest as required by any tax Act administered
1067	1067	6 by the Illinois Department of Revenue, until such time as the
1068	1068	7 requirements of any such tax Act are satisfied.
1069	1069	8 (b-5) The Department shall not revoke, suspend, summarily
1070	1070	9 suspend, place on prohibition, reprimand, refuse to issue or
1071	1071	10 renew, or take any other disciplinary or non-disciplinary
1072	1072	11 action against the license or permit issued under this Act to
1073	1073	12 practice as a physician assistant based solely upon the
1074	1074	13 physician assistant providing, authorizing, recommending,
1075	1075	14 aiding, assisting, referring for, or otherwise participating
1076	1076	15 in any health care service, so long as the care was not
1077	1077	16 unlawful under the laws of this State, regardless of whether
1078	1078	17 the patient was a resident of this State or another state.
1079	1079	18 (b-10) The Department shall not revoke, suspend, summarily
1080	1080	19 suspend, place on prohibition, reprimand, refuse to issue or
1081	1081	20 renew, or take any other disciplinary or non-disciplinary
1082	1082	21 action against the license or permit issued under this Act to
1083	1083	22 practice as a physician assistant based upon the physician
1084	1084	23 assistant's license being revoked or suspended, or the
1085	1085	24 physician assistant being otherwise disciplined by any other
1086	1086	25 state, if that revocation, suspension, or other form of
1087	1087	26 discipline was based solely on the physician assistant
1088	1088
1089	1089
1090	1090
1091	1091
1092	1092
1093	1093	HB2468 - 29 - LRB104 10667 AAS 20746 b
1094	1094
1095	1095
1096	1096	HB2468- 30 -LRB104 10667 AAS 20746 b HB2468 - 30 - LRB104 10667 AAS 20746 b
1097	1097	HB2468 - 30 - LRB104 10667 AAS 20746 b
1098	1098	1 violating another state's laws prohibiting the provision of,
1099	1099	2 authorization of, recommendation of, aiding or assisting in,
1100	1100	3 referring for, or participation in any health care service if
1101	1101	4 that health care service as provided would not have been
1102	1102	5 unlawful under the laws of this State and is consistent with
1103	1103	6 the standards of conduct for a physician assistant practicing
1104	1104	7 in Illinois.
1105	1105	8 (b-15) The conduct specified in subsections (b-5) and
1106	1106	9 (b-10) shall not constitute grounds for suspension under
1107	1107	10 Section 22.13.
1108	1108	11 (b-20) An applicant seeking licensure, certification, or
1109	1109	12 authorization pursuant to this Act who has been subject to
1110	1110	13 disciplinary action by a duly authorized professional
1111	1111	14 disciplinary agency of another jurisdiction solely on the
1112	1112	15 basis of having provided, authorized, recommended, aided,
1113	1113	16 assisted, referred for, or otherwise participated in health
1114	1114	17 care shall not be denied such licensure, certification, or
1115	1115	18 authorization, unless the Department determines that such
1116	1116	19 action would have constituted professional misconduct in this
1117	1117	20 State; however, nothing in this Section shall be construed as
1118	1118	21 prohibiting the Department from evaluating the conduct of such
1119	1119	22 applicant and making a determination regarding the licensure,
1120	1120	23 certification, or authorization to practice a profession under
1121	1121	24 this Act.
1122	1122	25 (c) The determination by a circuit court that a licensee
1123	1123	26 is subject to involuntary admission or judicial admission as
1124	1124
1125	1125
1126	1126
1127	1127
1128	1128
1129	1129	HB2468 - 30 - LRB104 10667 AAS 20746 b
1130	1130
1131	1131
1132	1132	HB2468- 31 -LRB104 10667 AAS 20746 b HB2468 - 31 - LRB104 10667 AAS 20746 b
1133	1133	HB2468 - 31 - LRB104 10667 AAS 20746 b
1134	1134	1 provided in the Mental Health and Developmental Disabilities
1135	1135	2 Code operates as an automatic suspension. The suspension will
1136	1136	3 end only upon a finding by a court that the patient is no
1137	1137	4 longer subject to involuntary admission or judicial admission
1138	1138	5 and issues an order so finding and discharging the patient,
1139	1139	6 and upon the recommendation of the Board to the Secretary that
1140	1140	7 the licensee be allowed to resume his or her practice.
1141	1141	8 (d) In enforcing this Section, the Department upon a
1142	1142	9 showing of a possible violation may compel an individual
1143	1143	10 licensed to practice under this Act, or who has applied for
1144	1144	11 licensure under this Act, to submit to a mental or physical
1145	1145	12 examination, or both, which may include a substance abuse or
1146	1146	13 sexual offender evaluation, as required by and at the expense
1147	1147	14 of the Department.
1148	1148	15 The Department shall specifically designate the examining
1149	1149	16 physician licensed to practice medicine in all of its branches
1150	1150	17 or, if applicable, the multidisciplinary team involved in
1151	1151	18 providing the mental or physical examination or both. The
1152	1152	19 multidisciplinary team shall be led by a physician licensed to
1153	1153	20 practice medicine in all of its branches and may consist of one
1154	1154	21 or more or a combination of physicians licensed to practice
1155	1155	22 medicine in all of its branches, licensed clinical
1156	1156	23 psychologists, licensed clinical social workers, licensed
1157	1157	24 clinical professional counselors, and other professional and
1158	1158	25 administrative staff. Any examining physician or member of the
1159	1159	26 multidisciplinary team may require any person ordered to
1160	1160
1161	1161
1162	1162
1163	1163
1164	1164
1165	1165	HB2468 - 31 - LRB104 10667 AAS 20746 b
1166	1166
1167	1167
1168	1168	HB2468- 32 -LRB104 10667 AAS 20746 b HB2468 - 32 - LRB104 10667 AAS 20746 b
1169	1169	HB2468 - 32 - LRB104 10667 AAS 20746 b
1170	1170	1 submit to an examination pursuant to this Section to submit to
1171	1171	2 any additional supplemental testing deemed necessary to
1172	1172	3 complete any examination or evaluation process, including, but
1173	1173	4 not limited to, blood testing, urinalysis, psychological
1174	1174	5 testing, or neuropsychological testing.
1175	1175	6 The Department may order the examining physician or any
1176	1176	7 member of the multidisciplinary team to provide to the
1177	1177	8 Department any and all records, including business records,
1178	1178	9 that relate to the examination and evaluation, including any
1179	1179	10 supplemental testing performed.
1180	1180	11 The Department may order the examining physician or any
1181	1181	12 member of the multidisciplinary team to present testimony
1182	1182	13 concerning the mental or physical examination of the licensee
1183	1183	14 or applicant. No information, report, record, or other
1184	1184	15 documents in any way related to the examination shall be
1185	1185	16 excluded by reason of any common law or statutory privilege
1186	1186	17 relating to communications between the licensee or applicant
1187	1187	18 and the examining physician or any member of the
1188	1188	19 multidisciplinary team. No authorization is necessary from the
1189	1189	20 licensee or applicant ordered to undergo an examination for
1190	1190	21 the examining physician or any member of the multidisciplinary
1191	1191	22 team to provide information, reports, records, or other
1192	1192	23 documents or to provide any testimony regarding the
1193	1193	24 examination and evaluation.
1194	1194	25 The individual to be examined may have, at his or her own
1195	1195	26 expense, another physician of his or her choice present during
1196	1196
1197	1197
1198	1198
1199	1199
1200	1200
1201	1201	HB2468 - 32 - LRB104 10667 AAS 20746 b
1202	1202
1203	1203
1204	1204	HB2468- 33 -LRB104 10667 AAS 20746 b HB2468 - 33 - LRB104 10667 AAS 20746 b
1205	1205	HB2468 - 33 - LRB104 10667 AAS 20746 b
1206	1206	1 all aspects of this examination. However, that physician shall
1207	1207	2 be present only to observe and may not interfere in any way
1208	1208	3 with the examination.
1209	1209	4 Failure of an individual to submit to a mental or physical
1210	1210	5 examination, when ordered, shall result in an automatic
1211	1211	6 suspension of his or her license until the individual submits
1212	1212	7 to the examination.
1213	1213	8 If the Department finds an individual unable to practice
1214	1214	9 because of the reasons set forth in this Section, the
1215	1215	10 Department may require that individual to submit to care,
1216	1216	11 counseling, or treatment by physicians approved or designated
1217	1217	12 by the Department, as a condition, term, or restriction for
1218	1218	13 continued, reinstated, or renewed licensure to practice; or,
1219	1219	14 in lieu of care, counseling, or treatment, the Department may
1220	1220	15 file a complaint to immediately suspend, revoke, or otherwise
1221	1221	16 discipline the license of the individual. An individual whose
1222	1222	17 license was granted, continued, reinstated, renewed,
1223	1223	18 disciplined, or supervised subject to such terms, conditions,
1224	1224	19 or restrictions, and who fails to comply with such terms,
1225	1225	20 conditions, or restrictions, shall be referred to the
1226	1226	21 Secretary for a determination as to whether the individual
1227	1227	22 shall have his or her license suspended immediately, pending a
1228	1228	23 hearing by the Department.
1229	1229	24 In instances in which the Secretary immediately suspends a
1230	1230	25 person's license under this Section, a hearing on that
1231	1231	26 person's license must be convened by the Department within 30
1232	1232
1233	1233
1234	1234
1235	1235
1236	1236
1237	1237	HB2468 - 33 - LRB104 10667 AAS 20746 b
1238	1238
1239	1239
1240	1240	HB2468- 34 -LRB104 10667 AAS 20746 b HB2468 - 34 - LRB104 10667 AAS 20746 b
1241	1241	HB2468 - 34 - LRB104 10667 AAS 20746 b
1242	1242	1 days after the suspension and completed without appreciable
1243	1243	2 delay. The Department shall have the authority to review the
1244	1244	3 subject individual's record of treatment and counseling
1245	1245	4 regarding the impairment to the extent permitted by applicable
1246	1246	5 federal statutes and regulations safeguarding the
1247	1247	6 confidentiality of medical records.
1248	1248	7 An individual licensed under this Act and affected under
1249	1249	8 this Section shall be afforded an opportunity to demonstrate
1250	1250	9 to the Department that he or she can resume practice in
1251	1251	10 compliance with acceptable and prevailing standards under the
1252	1252	11 provisions of his or her license.
1253	1253	12 (e) An individual or organization acting in good faith,
1254	1254	13 and not in a willful and wanton manner, in complying with this
1255	1255	14 Section by providing a report or other information to the
1256	1256	15 Board, by assisting in the investigation or preparation of a
1257	1257	16 report or information, by participating in proceedings of the
1258	1258	17 Board, or by serving as a member of the Board, shall not be
1259	1259	18 subject to criminal prosecution or civil damages as a result
1260	1260	19 of such actions.
1261	1261	20 (f) Members of the Board shall be indemnified by the State
1262	1262	21 for any actions occurring within the scope of services on the
1263	1263	22 Board, done in good faith and not willful and wanton in nature.
1264	1264	23 The Attorney General shall defend all such actions unless he
1265	1265	24 or she determines either that there would be a conflict of
1266	1266	25 interest in such representation or that the actions complained
1267	1267	26 of were not in good faith or were willful and wanton.
1268	1268
1269	1269
1270	1270
1271	1271
1272	1272
1273	1273	HB2468 - 34 - LRB104 10667 AAS 20746 b
1274	1274
1275	1275
1276	1276	HB2468- 35 -LRB104 10667 AAS 20746 b HB2468 - 35 - LRB104 10667 AAS 20746 b
1277	1277	HB2468 - 35 - LRB104 10667 AAS 20746 b
1278	1278	1 If the Attorney General declines representation, the
1279	1279	2 member has the right to employ counsel of his or her choice,
1280	1280	3 whose fees shall be provided by the State, after approval by
1281	1281	4 the Attorney General, unless there is a determination by a
1282	1282	5 court that the member's actions were not in good faith or were
1283	1283	6 willful and wanton.
1284	1284	7 The member must notify the Attorney General within 7 days
1285	1285	8 after receipt of notice of the initiation of any action
1286	1286	9 involving services of the Board. Failure to so notify the
1287	1287	10 Attorney General constitutes an absolute waiver of the right
1288	1288	11 to a defense and indemnification.
1289	1289	12 The Attorney General shall determine, within 7 days after
1290	1290	13 receiving such notice, whether he or she will undertake to
1291	1291	14 represent the member.
1292	1292	15 (g) The Department may adopt rules to implement the
1293	1293	16 changes made by this amendatory Act of the 102nd General
1294	1294	17 Assembly.
1295	1295	18 (Source: P.A. 101-363, eff. 8-9-19; 102-558, eff. 8-20-21;
1296	1296	19 102-1117, eff. 1-13-23.)
1297	1297	20 Section 10. The Illinois Controlled Substances Act is
1298	1298	21 amended by changing Sections 102 and 303.05 as follows:
1299	1299	22 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)
1300	1300	23 Sec. 102. Definitions. As used in this Act, unless the
1301	1301	24 context otherwise requires:
1302	1302
1303	1303
1304	1304
1305	1305
1306	1306
1307	1307	HB2468 - 35 - LRB104 10667 AAS 20746 b
1308	1308
1309	1309
1310	1310	HB2468- 36 -LRB104 10667 AAS 20746 b HB2468 - 36 - LRB104 10667 AAS 20746 b
1311	1311	HB2468 - 36 - LRB104 10667 AAS 20746 b
1312	1312	1 (a) "Person with a substance use disorder" means any
1313	1313	2 person who has a substance use disorder diagnosis defined as a
1314	1314	3 spectrum of persistent and recurring problematic behavior that
1315	1315	4 encompasses 10 separate classes of drugs: alcohol; caffeine;
1316	1316	5 cannabis; hallucinogens; inhalants; opioids; sedatives,
1317	1317	6 hypnotics and anxiolytics; stimulants; and tobacco; and other
1318	1318	7 unknown substances leading to clinically significant
1319	1319	8 impairment or distress.
1320	1320	9 (b) "Administer" means the direct application of a
1321	1321	10 controlled substance, whether by injection, inhalation,
1322	1322	11 ingestion, or any other means, to the body of a patient,
1323	1323	12 research subject, or animal (as defined by the Humane
1324	1324	13 Euthanasia in Animal Shelters Act) by:
1325	1325	14 (1) a practitioner (or, in his or her presence, by his
1326	1326	15 or her authorized agent),
1327	1327	16 (2) the patient or research subject pursuant to an
1328	1328	17 order, or
1329	1329	18 (3) a euthanasia technician as defined by the Humane
1330	1330	19 Euthanasia in Animal Shelters Act.
1331	1331	20 (c) "Agent" means an authorized person who acts on behalf
1332	1332	21 of or at the direction of a manufacturer, distributor,
1333	1333	22 dispenser, prescriber, or practitioner. It does not include a
1334	1334	23 common or contract carrier, public warehouseman or employee of
1335	1335	24 the carrier or warehouseman.
1336	1336	25 (c-1) "Anabolic Steroids" means any drug or hormonal
1337	1337	26 substance, chemically and pharmacologically related to
1338	1338
1339	1339
1340	1340
1341	1341
1342	1342
1343	1343	HB2468 - 36 - LRB104 10667 AAS 20746 b
1344	1344
1345	1345
1346	1346	HB2468- 37 -LRB104 10667 AAS 20746 b HB2468 - 37 - LRB104 10667 AAS 20746 b
1347	1347	HB2468 - 37 - LRB104 10667 AAS 20746 b
1348	1348	1 testosterone (other than estrogens, progestins,
1349	1349	2 corticosteroids, and dehydroepiandrosterone), and includes:
1350	1350	3 (i) 3[beta],17-dihydroxy-5a-androstane,
1351	1351	4 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
1352	1352	5 (iii) 5[alpha]-androstan-3,17-dione,
1353	1353	6 (iv) 1-androstenediol (3[beta],
1354	1354	7 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
1355	1355	8 (v) 1-androstenediol (3[alpha],
1356	1356	9 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
1357	1357	10 (vi) 4-androstenediol
1358	1358	11 (3[beta],17[beta]-dihydroxy-androst-4-ene),
1359	1359	12 (vii) 5-androstenediol
1360	1360	13 (3[beta],17[beta]-dihydroxy-androst-5-ene),
1361	1361	14 (viii) 1-androstenedione
1362	1362	15 ([5alpha]-androst-1-en-3,17-dione),
1363	1363	16 (ix) 4-androstenedione
1364	1364	17 (androst-4-en-3,17-dione),
1365	1365	18 (x) 5-androstenedione
1366	1366	19 (androst-5-en-3,17-dione),
1367	1367	20 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
1368	1368	21 hydroxyandrost-4-en-3-one),
1369	1369	22 (xii) boldenone (17[beta]-hydroxyandrost-
1370	1370	23 1,4,-diene-3-one),
1371	1371	24 (xiii) boldione (androsta-1,4-
1372	1372	25 diene-3,17-dione),
1373	1373	26 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
1374	1374
1375	1375
1376	1376
1377	1377
1378	1378
1379	1379	HB2468 - 37 - LRB104 10667 AAS 20746 b
1380	1380
1381	1381
1382	1382	HB2468- 38 -LRB104 10667 AAS 20746 b HB2468 - 38 - LRB104 10667 AAS 20746 b
1383	1383	HB2468 - 38 - LRB104 10667 AAS 20746 b
1384	1384	1 [beta]-hydroxyandrost-4-en-3-one),
1385	1385	2 (xv) clostebol (4-chloro-17[beta]-
1386	1386	3 hydroxyandrost-4-en-3-one),
1387	1387	4 (xvi) dehydrochloromethyltestosterone (4-chloro-
1388	1388	5 17[beta]-hydroxy-17[alpha]-methyl-
1389	1389	6 androst-1,4-dien-3-one),
1390	1390	7 (xvii) desoxymethyltestosterone
1391	1391	8 (17[alpha]-methyl-5[alpha]
1392	1392	9 -androst-2-en-17[beta]-ol)(a.k.a., madol),
1393	1393	10 (xviii) [delta]1-dihydrotestosterone (a.k.a.
1394	1394	11 '1-testosterone') (17[beta]-hydroxy-
1395	1395	12 5[alpha]-androst-1-en-3-one),
1396	1396	13 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
1397	1397	14 androstan-3-one),
1398	1398	15 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
1399	1399	16 5[alpha]-androstan-3-one),
1400	1400	17 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
1401	1401	18 hydroxyestr-4-ene),
1402	1402	19 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
1403	1403	20 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
1404	1404	21 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
1405	1405	22 17[beta]-dihydroxyandrost-1,4-dien-3-one),
1406	1406	23 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
1407	1407	24 hydroxyandrostano[2,3-c]-furazan),
1408	1408	25 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
1409	1409	26 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
1410	1410
1411	1411
1412	1412
1413	1413
1414	1414
1415	1415	HB2468 - 38 - LRB104 10667 AAS 20746 b
1416	1416
1417	1417
1418	1418	HB2468- 39 -LRB104 10667 AAS 20746 b HB2468 - 39 - LRB104 10667 AAS 20746 b
1419	1419	HB2468 - 39 - LRB104 10667 AAS 20746 b
1420	1420	1 androst-4-en-3-one),
1421	1421	2 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
1422	1422	3 dihydroxy-estr-4-en-3-one),
1423	1423	4 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
1424	1424	5 hydroxy-5-androstan-3-one),
1425	1425	6 (xxix) mesterolone (1amethyl-17[beta]-hydroxy-
1426	1426	7 [5a]-androstan-3-one),
1427	1427	8 (xxx) methandienone (17[alpha]-methyl-17[beta]-
1428	1428	9 hydroxyandrost-1,4-dien-3-one),
1429	1429	10 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
1430	1430	11 dihydroxyandrost-5-ene),
1431	1431	12 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
1432	1432	13 5[alpha]-androst-1-en-3-one),
1433	1433	14 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
1434	1434	15 dihydroxy-5a-androstane,
1435	1435	16 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
1436	1436	17 -5a-androstane,
1437	1437	18 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
1438	1438	19 dihydroxyandrost-4-ene),
1439	1439	20 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
1440	1440	21 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
1441	1441	22 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
1442	1442	23 hydroxyestra-4,9(10)-dien-3-one),
1443	1443	24 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
1444	1444	25 hydroxyestra-4,9-11-trien-3-one),
1445	1445	26 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
1446	1446
1447	1447
1448	1448
1449	1449
1450	1450
1451	1451	HB2468 - 39 - LRB104 10667 AAS 20746 b
1452	1452
1453	1453
1454	1454	HB2468- 40 -LRB104 10667 AAS 20746 b HB2468 - 40 - LRB104 10667 AAS 20746 b
1455	1455	HB2468 - 40 - LRB104 10667 AAS 20746 b
1456	1456	1 hydroxyandrost-4-en-3-one),
1457	1457	2 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
1458	1458	3 hydroxyestr-4-en-3-one),
1459	1459	4 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
1460	1460	5 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
1461	1461	6 androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
1462	1462	7 1-testosterone'),
1463	1463	8 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
1464	1464	9 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
1465	1465	10 dihydroxyestr-4-ene),
1466	1466	11 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
1467	1467	12 dihydroxyestr-4-ene),
1468	1468	13 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
1469	1469	14 dihydroxyestr-5-ene),
1470	1470	15 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
1471	1471	16 dihydroxyestr-5-ene),
1472	1472	17 (xlvii) 19-nor-4,9(10)-androstadienedione
1473	1473	18 (estra-4,9(10)-diene-3,17-dione),
1474	1474	19 (xlviii) 19-nor-4-androstenedione (estr-4-
1475	1475	20 en-3,17-dione),
1476	1476	21 (xlix) 19-nor-5-androstenedione (estr-5-
1477	1477	22 en-3,17-dione),
1478	1478	23 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
1479	1479	24 hydroxygon-4-en-3-one),
1480	1480	25 (li) norclostebol (4-chloro-17[beta]-
1481	1481	26 hydroxyestr-4-en-3-one),
1482	1482
1483	1483
1484	1484
1485	1485
1486	1486
1487	1487	HB2468 - 40 - LRB104 10667 AAS 20746 b
1488	1488
1489	1489
1490	1490	HB2468- 41 -LRB104 10667 AAS 20746 b HB2468 - 41 - LRB104 10667 AAS 20746 b
1491	1491	HB2468 - 41 - LRB104 10667 AAS 20746 b
1492	1492	1 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
1493	1493	2 hydroxyestr-4-en-3-one),
1494	1494	3 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
1495	1495	4 hydroxyestr-4-en-3-one),
1496	1496	5 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
1497	1497	6 2-oxa-5[alpha]-androstan-3-one),
1498	1498	7 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
1499	1499	8 dihydroxyandrost-4-en-3-one),
1500	1500	9 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
1501	1501	10 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
1502	1502	11 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
1503	1503	12 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
1504	1504	13 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
1505	1505	14 (5[alpha]-androst-1-en-3-one),
1506	1506	15 (lix) testolactone (13-hydroxy-3-oxo-13,17-
1507	1507	16 secoandrosta-1,4-dien-17-oic
1508	1508	17 acid lactone),
1509	1509	18 (lx) testosterone (17[beta]-hydroxyandrost-
1510	1510	19 4-en-3-one),
1511	1511	20 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
1512	1512	21 diethyl-17[beta]-hydroxygon-
1513	1513	22 4,9,11-trien-3-one),
1514	1514	23 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
1515	1515	24 11-trien-3-one).
1516	1516	25 Any person who is otherwise lawfully in possession of an
1517	1517	26 anabolic steroid, or who otherwise lawfully manufactures,
1518	1518
1519	1519
1520	1520
1521	1521
1522	1522
1523	1523	HB2468 - 41 - LRB104 10667 AAS 20746 b
1524	1524
1525	1525
1526	1526	HB2468- 42 -LRB104 10667 AAS 20746 b HB2468 - 42 - LRB104 10667 AAS 20746 b
1527	1527	HB2468 - 42 - LRB104 10667 AAS 20746 b
1528	1528	1 distributes, dispenses, delivers, or possesses with intent to
1529	1529	2 deliver an anabolic steroid, which anabolic steroid is
1530	1530	3 expressly intended for and lawfully allowed to be administered
1531	1531	4 through implants to livestock or other nonhuman species, and
1532	1532	5 which is approved by the Secretary of Health and Human
1533	1533	6 Services for such administration, and which the person intends
1534	1534	7 to administer or have administered through such implants,
1535	1535	8 shall not be considered to be in unauthorized possession or to
1536	1536	9 unlawfully manufacture, distribute, dispense, deliver, or
1537	1537	10 possess with intent to deliver such anabolic steroid for
1538	1538	11 purposes of this Act.
1539	1539	12 (d) "Administration" means the Drug Enforcement
1540	1540	13 Administration, United States Department of Justice, or its
1541	1541	14 successor agency.
1542	1542	15 (d-5) "Clinical Director, Prescription Monitoring Program"
1543	1543	16 means a Department of Human Services administrative employee
1544	1544	17 licensed to either prescribe or dispense controlled substances
1545	1545	18 who shall run the clinical aspects of the Department of Human
1546	1546	19 Services Prescription Monitoring Program and its Prescription
1547	1547	20 Information Library.
1548	1548	21 (d-10) "Compounding" means the preparation and mixing of
1549	1549	22 components, excluding flavorings, (1) as the result of a
1550	1550	23 prescriber's prescription drug order or initiative based on
1551	1551	24 the prescriber-patient-pharmacist relationship in the course
1552	1552	25 of professional practice or (2) for the purpose of, or
1553	1553	26 incident to, research, teaching, or chemical analysis and not
1554	1554
1555	1555
1556	1556
1557	1557
1558	1558
1559	1559	HB2468 - 42 - LRB104 10667 AAS 20746 b
1560	1560
1561	1561
1562	1562	HB2468- 43 -LRB104 10667 AAS 20746 b HB2468 - 43 - LRB104 10667 AAS 20746 b
1563	1563	HB2468 - 43 - LRB104 10667 AAS 20746 b
1564	1564	1 for sale or dispensing. "Compounding" includes the preparation
1565	1565	2 of drugs or devices in anticipation of receiving prescription
1566	1566	3 drug orders based on routine, regularly observed dispensing
1567	1567	4 patterns. Commercially available products may be compounded
1568	1568	5 for dispensing to individual patients only if both of the
1569	1569	6 following conditions are met: (i) the commercial product is
1570	1570	7 not reasonably available from normal distribution channels in
1571	1571	8 a timely manner to meet the patient's needs and (ii) the
1572	1572	9 prescribing practitioner has requested that the drug be
1573	1573	10 compounded.
1574	1574	11 (e) "Control" means to add a drug or other substance, or
1575	1575	12 immediate precursor, to a Schedule whether by transfer from
1576	1576	13 another Schedule or otherwise.
1577	1577	14 (f) "Controlled Substance" means (i) a drug, substance,
1578	1578	15 immediate precursor, or synthetic drug in the Schedules of
1579	1579	16 Article II of this Act or (ii) a drug or other substance, or
1580	1580	17 immediate precursor, designated as a controlled substance by
1581	1581	18 the Department through administrative rule. The term does not
1582	1582	19 include distilled spirits, wine, malt beverages, or tobacco,
1583	1583	20 as those terms are defined or used in the Liquor Control Act of
1584	1584	21 1934 and the Tobacco Products Tax Act of 1995.
1585	1585	22 (f-5) "Controlled substance analog" means a substance:
1586	1586	23 (1) the chemical structure of which is substantially
1587	1587	24 similar to the chemical structure of a controlled
1588	1588	25 substance in Schedule I or II;
1589	1589	26 (2) which has a stimulant, depressant, or
1590	1590
1591	1591
1592	1592
1593	1593
1594	1594
1595	1595	HB2468 - 43 - LRB104 10667 AAS 20746 b
1596	1596
1597	1597
1598	1598	HB2468- 44 -LRB104 10667 AAS 20746 b HB2468 - 44 - LRB104 10667 AAS 20746 b
1599	1599	HB2468 - 44 - LRB104 10667 AAS 20746 b
1600	1600	1 hallucinogenic effect on the central nervous system that
1601	1601	2 is substantially similar to or greater than the stimulant,
1602	1602	3 depressant, or hallucinogenic effect on the central
1603	1603	4 nervous system of a controlled substance in Schedule I or
1604	1604	5 II; or
1605	1605	6 (3) with respect to a particular person, which such
1606	1606	7 person represents or intends to have a stimulant,
1607	1607	8 depressant, or hallucinogenic effect on the central
1608	1608	9 nervous system that is substantially similar to or greater
1609	1609	10 than the stimulant, depressant, or hallucinogenic effect
1610	1610	11 on the central nervous system of a controlled substance in
1611	1611	12 Schedule I or II.
1612	1612	13 (g) "Counterfeit substance" means a controlled substance,
1613	1613	14 which, or the container or labeling of which, without
1614	1614	15 authorization bears the trademark, trade name, or other
1615	1615	16 identifying mark, imprint, number or device, or any likeness
1616	1616	17 thereof, of a manufacturer, distributor, or dispenser other
1617	1617	18 than the person who in fact manufactured, distributed, or
1618	1618	19 dispensed the substance.
1619	1619	20 (h) "Deliver" or "delivery" means the actual, constructive
1620	1620	21 or attempted transfer of possession of a controlled substance,
1621	1621	22 with or without consideration, whether or not there is an
1622	1622	23 agency relationship. "Deliver" or "delivery" does not include
1623	1623	24 the donation of drugs to the extent permitted under the
1624	1624	25 Illinois Drug Reuse Opportunity Program Act.
1625	1625	26 (i) "Department" means the Illinois Department of Human
1626	1626
1627	1627
1628	1628
1629	1629
1630	1630
1631	1631	HB2468 - 44 - LRB104 10667 AAS 20746 b
1632	1632
1633	1633
1634	1634	HB2468- 45 -LRB104 10667 AAS 20746 b HB2468 - 45 - LRB104 10667 AAS 20746 b
1635	1635	HB2468 - 45 - LRB104 10667 AAS 20746 b
1636	1636	1 Services (as successor to the Department of Alcoholism and
1637	1637	2 Substance Abuse) or its successor agency.
1638	1638	3 (j) (Blank).
1639	1639	4 (k) "Department of Corrections" means the Department of
1640	1640	5 Corrections of the State of Illinois or its successor agency.
1641	1641	6 (l) "Department of Financial and Professional Regulation"
1642	1642	7 means the Department of Financial and Professional Regulation
1643	1643	8 of the State of Illinois or its successor agency.
1644	1644	9 (m) "Depressant" means any drug that (i) causes an overall
1645	1645	10 depression of central nervous system functions, (ii) causes
1646	1646	11 impaired consciousness and awareness, and (iii) can be
1647	1647	12 habit-forming or lead to a substance misuse or substance use
1648	1648	13 disorder, including, but not limited to, alcohol, cannabis and
1649	1649	14 its active principles and their analogs, benzodiazepines and
1650	1650	15 their analogs, barbiturates and their analogs, opioids
1651	1651	16 (natural and synthetic) and their analogs, and chloral hydrate
1652	1652	17 and similar sedative hypnotics.
1653	1653	18 (n) (Blank).
1654	1654	19 (o) "Director" means the Director of the Illinois State
1655	1655	20 Police or his or her designated agents.
1656	1656	21 (p) "Dispense" means to deliver a controlled substance to
1657	1657	22 an ultimate user or research subject by or pursuant to the
1658	1658	23 lawful order of a prescriber, including the prescribing,
1659	1659	24 administering, packaging, labeling, or compounding necessary
1660	1660	25 to prepare the substance for that delivery.
1661	1661	26 (q) "Dispenser" means a practitioner who dispenses.
1662	1662
1663	1663
1664	1664
1665	1665
1666	1666
1667	1667	HB2468 - 45 - LRB104 10667 AAS 20746 b
1668	1668
1669	1669
1670	1670	HB2468- 46 -LRB104 10667 AAS 20746 b HB2468 - 46 - LRB104 10667 AAS 20746 b
1671	1671	HB2468 - 46 - LRB104 10667 AAS 20746 b
1672	1672	1 (r) "Distribute" means to deliver, other than by
1673	1673	2 administering or dispensing, a controlled substance.
1674	1674	3 (s) "Distributor" means a person who distributes.
1675	1675	4 (t) "Drug" means (1) substances recognized as drugs in the
1676	1676	5 official United States Pharmacopoeia, Official Homeopathic
1677	1677	6 Pharmacopoeia of the United States, or official National
1678	1678	7 Formulary, or any supplement to any of them; (2) substances
1679	1679	8 intended for use in diagnosis, cure, mitigation, treatment, or
1680	1680	9 prevention of disease in man or animals; (3) substances (other
1681	1681	10 than food) intended to affect the structure of any function of
1682	1682	11 the body of man or animals and (4) substances intended for use
1683	1683	12 as a component of any article specified in clause (1), (2), or
1684	1684	13 (3) of this subsection. It does not include devices or their
1685	1685	14 components, parts, or accessories.
1686	1686	15 (t-3) "Electronic health record" or "EHR" means an
1687	1687	16 electronic record of health-related information on an
1688	1688	17 individual that is created, gathered, managed, and consulted
1689	1689	18 by authorized health care clinicians and staff.
1690	1690	19 (t-3.5) "Electronic health record system" or "EHR system"
1691	1691	20 means any computer-based system or combination of federally
1692	1692	21 certified Health IT Modules (defined at 42 CFR 170.102 or its
1693	1693	22 successor) used as a repository for electronic health records
1694	1694	23 and accessed or updated by a prescriber or authorized
1695	1695	24 surrogate in the ordinary course of his or her medical
1696	1696	25 practice. For purposes of connecting to the Prescription
1697	1697	26 Information Library maintained by the Bureau of Pharmacy and
1698	1698
1699	1699
1700	1700
1701	1701
1702	1702
1703	1703	HB2468 - 46 - LRB104 10667 AAS 20746 b
1704	1704
1705	1705
1706	1706	HB2468- 47 -LRB104 10667 AAS 20746 b HB2468 - 47 - LRB104 10667 AAS 20746 b
1707	1707	HB2468 - 47 - LRB104 10667 AAS 20746 b
1708	1708	1 Clinical Support Systems or its successor, an EHR system may
1709	1709	2 connect to the Prescription Information Library directly or
1710	1710	3 through all or part of a computer program or system that is a
1711	1711	4 federally certified Health IT Module maintained by a third
1712	1712	5 party and used by the EHR system to secure access to the
1713	1713	6 database.
1714	1714	7 (t-4) "Emergency medical services personnel" has the
1715	1715	8 meaning ascribed to it in the Emergency Medical Services (EMS)
1716	1716	9 Systems Act.
1717	1717	10 (t-5) "Euthanasia agency" means an entity certified by the
1718	1718	11 Department of Financial and Professional Regulation for the
1719	1719	12 purpose of animal euthanasia that holds an animal control
1720	1720	13 facility license or animal shelter license under the Animal
1721	1721	14 Welfare Act. A euthanasia agency is authorized to purchase,
1722	1722	15 store, possess, and utilize Schedule II nonnarcotic and
1723	1723	16 Schedule III nonnarcotic drugs for the sole purpose of animal
1724	1724	17 euthanasia.
1725	1725	18 (t-10) "Euthanasia drugs" means Schedule II or Schedule
1726	1726	19 III substances (nonnarcotic controlled substances) that are
1727	1727	20 used by a euthanasia agency for the purpose of animal
1728	1728	21 euthanasia.
1729	1729	22 (u) "Good faith" means the prescribing or dispensing of a
1730	1730	23 controlled substance by a practitioner in the regular course
1731	1731	24 of professional treatment to or for any person who is under his
1732	1732	25 or her treatment for a pathology or condition other than that
1733	1733	26 individual's physical or psychological dependence upon a
1734	1734
1735	1735
1736	1736
1737	1737
1738	1738
1739	1739	HB2468 - 47 - LRB104 10667 AAS 20746 b
1740	1740
1741	1741
1742	1742	HB2468- 48 -LRB104 10667 AAS 20746 b HB2468 - 48 - LRB104 10667 AAS 20746 b
1743	1743	HB2468 - 48 - LRB104 10667 AAS 20746 b
1744	1744	1 controlled substance, except as provided herein: and
1745	1745	2 application of the term to a pharmacist shall mean the
1746	1746	3 dispensing of a controlled substance pursuant to the
1747	1747	4 prescriber's order which in the professional judgment of the
1748	1748	5 pharmacist is lawful. The pharmacist shall be guided by
1749	1749	6 accepted professional standards, including, but not limited
1750	1750	7 to, the following, in making the judgment:
1751	1751	8 (1) lack of consistency of prescriber-patient
1752	1752	9 relationship,
1753	1753	10 (2) frequency of prescriptions for same drug by one
1754	1754	11 prescriber for large numbers of patients,
1755	1755	12 (3) quantities beyond those normally prescribed,
1756	1756	13 (4) unusual dosages (recognizing that there may be
1757	1757	14 clinical circumstances where more or less than the usual
1758	1758	15 dose may be used legitimately),
1759	1759	16 (5) unusual geographic distances between patient,
1760	1760	17 pharmacist and prescriber,
1761	1761	18 (6) consistent prescribing of habit-forming drugs.
1762	1762	19 (u-0.5) "Hallucinogen" means a drug that causes markedly
1763	1763	20 altered sensory perception leading to hallucinations of any
1764	1764	21 type.
1765	1765	22 (u-1) "Home infusion services" means services provided by
1766	1766	23 a pharmacy in compounding solutions for direct administration
1767	1767	24 to a patient in a private residence, long-term care facility,
1768	1768	25 or hospice setting by means of parenteral, intravenous,
1769	1769	26 intramuscular, subcutaneous, or intraspinal infusion.
1770	1770
1771	1771
1772	1772
1773	1773
1774	1774
1775	1775	HB2468 - 48 - LRB104 10667 AAS 20746 b
1776	1776
1777	1777
1778	1778	HB2468- 49 -LRB104 10667 AAS 20746 b HB2468 - 49 - LRB104 10667 AAS 20746 b
1779	1779	HB2468 - 49 - LRB104 10667 AAS 20746 b
1780	1780	1 (u-5) "Illinois State Police" means the Illinois State
1781	1781	2 Police or its successor agency.
1782	1782	3 (v) "Immediate precursor" means a substance:
1783	1783	4 (1) which the Department has found to be and by rule
1784	1784	5 designated as being a principal compound used, or produced
1785	1785	6 primarily for use, in the manufacture of a controlled
1786	1786	7 substance;
1787	1787	8 (2) which is an immediate chemical intermediary used
1788	1788	9 or likely to be used in the manufacture of such controlled
1789	1789	10 substance; and
1790	1790	11 (3) the control of which is necessary to prevent,
1791	1791	12 curtail or limit the manufacture of such controlled
1792	1792	13 substance.
1793	1793	14 (w) "Instructional activities" means the acts of teaching,
1794	1794	15 educating or instructing by practitioners using controlled
1795	1795	16 substances within educational facilities approved by the State
1796	1796	17 Board of Education or its successor agency.
1797	1797	18 (x) "Local authorities" means a duly organized State,
1798	1798	19 County or Municipal peace unit or police force.
1799	1799	20 (y) "Look-alike substance" means a substance, other than a
1800	1800	21 controlled substance which (1) by overall dosage unit
1801	1801	22 appearance, including shape, color, size, markings or lack
1802	1802	23 thereof, taste, consistency, or any other identifying physical
1803	1803	24 characteristic of the substance, would lead a reasonable
1804	1804	25 person to believe that the substance is a controlled
1805	1805	26 substance, or (2) is expressly or impliedly represented to be
1806	1806
1807	1807
1808	1808
1809	1809
1810	1810
1811	1811	HB2468 - 49 - LRB104 10667 AAS 20746 b
1812	1812
1813	1813
1814	1814	HB2468- 50 -LRB104 10667 AAS 20746 b HB2468 - 50 - LRB104 10667 AAS 20746 b
1815	1815	HB2468 - 50 - LRB104 10667 AAS 20746 b
1816	1816	1 a controlled substance or is distributed under circumstances
1817	1817	2 which would lead a reasonable person to believe that the
1818	1818	3 substance is a controlled substance. For the purpose of
1819	1819	4 determining whether the representations made or the
1820	1820	5 circumstances of the distribution would lead a reasonable
1821	1821	6 person to believe the substance to be a controlled substance
1822	1822	7 under this clause (2) of subsection (y), the court or other
1823	1823	8 authority may consider the following factors in addition to
1824	1824	9 any other factor that may be relevant:
1825	1825	10 (a) statements made by the owner or person in control
1826	1826	11 of the substance concerning its nature, use or effect;
1827	1827	12 (b) statements made to the buyer or recipient that the
1828	1828	13 substance may be resold for profit;
1829	1829	14 (c) whether the substance is packaged in a manner
1830	1830	15 normally used for the illegal distribution of controlled
1831	1831	16 substances;
1832	1832	17 (d) whether the distribution or attempted distribution
1833	1833	18 included an exchange of or demand for money or other
1834	1834	19 property as consideration, and whether the amount of the
1835	1835	20 consideration was substantially greater than the
1836	1836	21 reasonable retail market value of the substance.
1837	1837	22 Clause (1) of this subsection (y) shall not apply to a
1838	1838	23 noncontrolled substance in its finished dosage form that was
1839	1839	24 initially introduced into commerce prior to the initial
1840	1840	25 introduction into commerce of a controlled substance in its
1841	1841	26 finished dosage form which it may substantially resemble.
1842	1842
1843	1843
1844	1844
1845	1845
1846	1846
1847	1847	HB2468 - 50 - LRB104 10667 AAS 20746 b
1848	1848
1849	1849
1850	1850	HB2468- 51 -LRB104 10667 AAS 20746 b HB2468 - 51 - LRB104 10667 AAS 20746 b
1851	1851	HB2468 - 51 - LRB104 10667 AAS 20746 b
1852	1852	1 Nothing in this subsection (y) prohibits the dispensing or
1853	1853	2 distributing of noncontrolled substances by persons authorized
1854	1854	3 to dispense and distribute controlled substances under this
1855	1855	4 Act, provided that such action would be deemed to be carried
1856	1856	5 out in good faith under subsection (u) if the substances
1857	1857	6 involved were controlled substances.
1858	1858	7 Nothing in this subsection (y) or in this Act prohibits
1859	1859	8 the manufacture, preparation, propagation, compounding,
1860	1860	9 processing, packaging, advertising or distribution of a drug
1861	1861	10 or drugs by any person registered pursuant to Section 510 of
1862	1862	11 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
1863	1863	12 (y-1) "Mail-order pharmacy" means a pharmacy that is
1864	1864	13 located in a state of the United States that delivers,
1865	1865	14 dispenses or distributes, through the United States Postal
1866	1866	15 Service or other common carrier, to Illinois residents, any
1867	1867	16 substance which requires a prescription.
1868	1868	17 (z) "Manufacture" means the production, preparation,
1869	1869	18 propagation, compounding, conversion or processing of a
1870	1870	19 controlled substance other than methamphetamine, either
1871	1871	20 directly or indirectly, by extraction from substances of
1872	1872	21 natural origin, or independently by means of chemical
1873	1873	22 synthesis, or by a combination of extraction and chemical
1874	1874	23 synthesis, and includes any packaging or repackaging of the
1875	1875	24 substance or labeling of its container, except that this term
1876	1876	25 does not include:
1877	1877	26 (1) by an ultimate user, the preparation or
1878	1878
1879	1879
1880	1880
1881	1881
1882	1882
1883	1883	HB2468 - 51 - LRB104 10667 AAS 20746 b
1884	1884
1885	1885
1886	1886	HB2468- 52 -LRB104 10667 AAS 20746 b HB2468 - 52 - LRB104 10667 AAS 20746 b
1887	1887	HB2468 - 52 - LRB104 10667 AAS 20746 b
1888	1888	1 compounding of a controlled substance for his or her own
1889	1889	2 use;
1890	1890	3 (2) by a practitioner, or his or her authorized agent
1891	1891	4 under his or her supervision, the preparation,
1892	1892	5 compounding, packaging, or labeling of a controlled
1893	1893	6 substance:
1894	1894	7 (a) as an incident to his or her administering or
1895	1895	8 dispensing of a controlled substance in the course of
1896	1896	9 his or her professional practice; or
1897	1897	10 (b) as an incident to lawful research, teaching or
1898	1898	11 chemical analysis and not for sale; or
1899	1899	12 (3) the packaging, repackaging, or labeling of drugs
1900	1900	13 only to the extent permitted under the Illinois Drug Reuse
1901	1901	14 Opportunity Program Act.
1902	1902	15 (z-1) (Blank).
1903	1903	16 (z-5) "Medication shopping" means the conduct prohibited
1904	1904	17 under subsection (a) of Section 314.5 of this Act.
1905	1905	18 (z-10) "Mid-level practitioner" means (i) a physician
1906	1906	19 assistant who has been delegated authority to prescribe
1907	1907	20 through a written delegation of authority by a physician
1908	1908	21 licensed to practice medicine in all of its branches, in
1909	1909	22 accordance with Section 7.5 of the Physician Assistant
1910	1910	23 Practice Act of 1987, (ii) an advanced practice registered
1911	1911	24 nurse who has been delegated authority to prescribe through a
1912	1912	25 written delegation of authority by a physician licensed to
1913	1913	26 practice medicine in all of its branches or by a podiatric
1914	1914
1915	1915
1916	1916
1917	1917
1918	1918
1919	1919	HB2468 - 52 - LRB104 10667 AAS 20746 b
1920	1920
1921	1921
1922	1922	HB2468- 53 -LRB104 10667 AAS 20746 b HB2468 - 53 - LRB104 10667 AAS 20746 b
1923	1923	HB2468 - 53 - LRB104 10667 AAS 20746 b
1924	1924	1 physician, in accordance with Section 65-40 of the Nurse
1925	1925	2 Practice Act, (iii) an advanced practice registered nurse
1926	1926	3 certified as a nurse practitioner, nurse midwife, or clinical
1927	1927	4 nurse specialist who has been granted authority to prescribe
1928	1928	5 by a hospital affiliate in accordance with Section 65-45 of
1929	1929	6 the Nurse Practice Act, (iv) an animal euthanasia agency, or
1930	1930	7 (v) a prescribing psychologist.
1931	1931	8 (aa) "Narcotic drug" means any of the following, whether
1932	1932	9 produced directly or indirectly by extraction from substances
1933	1933	10 of vegetable origin, or independently by means of chemical
1934	1934	11 synthesis, or by a combination of extraction and chemical
1935	1935	12 synthesis:
1936	1936	13 (1) opium, opiates, derivatives of opium and opiates,
1937	1937	14 including their isomers, esters, ethers, salts, and salts
1938	1938	15 of isomers, esters, and ethers, whenever the existence of
1939	1939	16 such isomers, esters, ethers, and salts is possible within
1940	1940	17 the specific chemical designation; however the term
1941	1941	18 "narcotic drug" does not include the isoquinoline
1942	1942	19 alkaloids of opium;
1943	1943	20 (2) (blank);
1944	1944	21 (3) opium poppy and poppy straw;
1945	1945	22 (4) coca leaves, except coca leaves and extracts of
1946	1946	23 coca leaves from which substantially all of the cocaine
1947	1947	24 and ecgonine, and their isomers, derivatives and salts,
1948	1948	25 have been removed;
1949	1949	26 (5) cocaine, its salts, optical and geometric isomers,
1950	1950
1951	1951
1952	1952
1953	1953
1954	1954
1955	1955	HB2468 - 53 - LRB104 10667 AAS 20746 b
1956	1956
1957	1957
1958	1958	HB2468- 54 -LRB104 10667 AAS 20746 b HB2468 - 54 - LRB104 10667 AAS 20746 b
1959	1959	HB2468 - 54 - LRB104 10667 AAS 20746 b
1960	1960	1 and salts of isomers;
1961	1961	2 (6) ecgonine, its derivatives, their salts, isomers,
1962	1962	3 and salts of isomers;
1963	1963	4 (7) any compound, mixture, or preparation which
1964	1964	5 contains any quantity of any of the substances referred to
1965	1965	6 in subparagraphs (1) through (6).
1966	1966	7 (bb) "Nurse" means a registered nurse licensed under the
1967	1967	8 Nurse Practice Act.
1968	1968	9 (cc) (Blank).
1969	1969	10 (dd) "Opiate" means a drug derived from or related to
1970	1970	11 opium.
1971	1971	12 (ee) "Opium poppy" means the plant of the species Papaver
1972	1972	13 somniferum L., except its seeds.
1973	1973	14 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
1974	1974	15 solution or other liquid form of medication intended for
1975	1975	16 administration by mouth, but the term does not include a form
1976	1976	17 of medication intended for buccal, sublingual, or transmucosal
1977	1977	18 administration.
1978	1978	19 (ff) "Parole and Pardon Board" means the Parole and Pardon
1979	1979	20 Board of the State of Illinois or its successor agency.
1980	1980	21 (gg) "Person" means any individual, corporation,
1981	1981	22 mail-order pharmacy, government or governmental subdivision or
1982	1982	23 agency, business trust, estate, trust, partnership or
1983	1983	24 association, or any other entity.
1984	1984	25 (hh) "Pharmacist" means any person who holds a license or
1985	1985	26 certificate of registration as a registered pharmacist, a
1986	1986
1987	1987
1988	1988
1989	1989
1990	1990
1991	1991	HB2468 - 54 - LRB104 10667 AAS 20746 b
1992	1992
1993	1993
1994	1994	HB2468- 55 -LRB104 10667 AAS 20746 b HB2468 - 55 - LRB104 10667 AAS 20746 b
1995	1995	HB2468 - 55 - LRB104 10667 AAS 20746 b
1996	1996	1 local registered pharmacist or a registered assistant
1997	1997	2 pharmacist under the Pharmacy Practice Act.
1998	1998	3 (ii) "Pharmacy" means any store, ship or other place in
1999	1999	4 which pharmacy is authorized to be practiced under the
2000	2000	5 Pharmacy Practice Act.
2001	2001	6 (ii-5) "Pharmacy shopping" means the conduct prohibited
2002	2002	7 under subsection (b) of Section 314.5 of this Act.
2003	2003	8 (ii-10) "Physician" (except when the context otherwise
2004	2004	9 requires) means a person licensed to practice medicine in all
2005	2005	10 of its branches.
2006	2006	11 (jj) "Poppy straw" means all parts, except the seeds, of
2007	2007	12 the opium poppy, after mowing.
2008	2008	13 (kk) "Practitioner" means a physician licensed to practice
2009	2009	14 medicine in all its branches, dentist, optometrist, podiatric
2010	2010	15 physician, veterinarian, scientific investigator, pharmacist,
2011	2011	16 physician assistant, advanced practice registered nurse,
2012	2012	17 licensed practical nurse, registered nurse, emergency medical
2013	2013	18 services personnel, hospital, laboratory, or pharmacy, or
2014	2014	19 other person licensed, registered, or otherwise lawfully
2015	2015	20 permitted by the United States or this State to distribute,
2016	2016	21 dispense, conduct research with respect to, administer or use
2017	2017	22 in teaching or chemical analysis, a controlled substance in
2018	2018	23 the course of professional practice or research.
2019	2019	24 (ll) "Pre-printed prescription" means a written
2020	2020	25 prescription upon which the designated drug has been indicated
2021	2021	26 prior to the time of issuance; the term does not mean a written
2022	2022
2023	2023
2024	2024
2025	2025
2026	2026
2027	2027	HB2468 - 55 - LRB104 10667 AAS 20746 b
2028	2028
2029	2029
2030	2030	HB2468- 56 -LRB104 10667 AAS 20746 b HB2468 - 56 - LRB104 10667 AAS 20746 b
2031	2031	HB2468 - 56 - LRB104 10667 AAS 20746 b
2032	2032	1 prescription that is individually generated by machine or
2033	2033	2 computer in the prescriber's office.
2034	2034	3 (mm) "Prescriber" means a physician licensed to practice
2035	2035	4 medicine in all its branches, dentist, optometrist,
2036	2036	5 prescribing psychologist licensed under Section 4.2 of the
2037	2037	6 Clinical Psychologist Licensing Act with prescriptive
2038	2038	7 authority delegated under Section 4.3 of the Clinical
2039	2039	8 Psychologist Licensing Act, podiatric physician, or
2040	2040	9 veterinarian who issues a prescription, a physician assistant
2041	2041	10 who issues a prescription for a controlled substance in
2042	2042	11 accordance with Section 303.05, a written delegation, and a
2043	2043	12 written collaborative agreement required under Section 7.5 of
2044	2044	13 the Physician Assistant Practice Act of 1987, an advanced
2045	2045	14 practice registered nurse with prescriptive authority
2046	2046	15 delegated under Section 65-40 of the Nurse Practice Act and in
2047	2047	16 accordance with Section 303.05, a written delegation, and a
2048	2048	17 written collaborative agreement under Section 65-35 of the
2049	2049	18 Nurse Practice Act, an advanced practice registered nurse
2050	2050	19 certified as a nurse practitioner, nurse midwife, or clinical
2051	2051	20 nurse specialist who has been granted authority to prescribe
2052	2052	21 by a hospital affiliate in accordance with Section 65-45 of
2053	2053	22 the Nurse Practice Act and in accordance with Section 303.05,
2054	2054	23 or an advanced practice registered nurse certified as a nurse
2055	2055	24 practitioner, nurse midwife, or clinical nurse specialist who
2056	2056	25 has full practice authority pursuant to Section 65-43 of the
2057	2057	26 Nurse Practice Act.
2058	2058
2059	2059
2060	2060
2061	2061
2062	2062
2063	2063	HB2468 - 56 - LRB104 10667 AAS 20746 b
2064	2064
2065	2065
2066	2066	HB2468- 57 -LRB104 10667 AAS 20746 b HB2468 - 57 - LRB104 10667 AAS 20746 b
2067	2067	HB2468 - 57 - LRB104 10667 AAS 20746 b
2068	2068	1 (nn) "Prescription" means a written, facsimile, or oral
2069	2069	2 order, or an electronic order that complies with applicable
2070	2070	3 federal requirements, of a physician licensed to practice
2071	2071	4 medicine in all its branches, dentist, podiatric physician or
2072	2072	5 veterinarian for any controlled substance, of an optometrist
2073	2073	6 in accordance with Section 15.1 of the Illinois Optometric
2074	2074	7 Practice Act of 1987, of a prescribing psychologist licensed
2075	2075	8 under Section 4.2 of the Clinical Psychologist Licensing Act
2076	2076	9 with prescriptive authority delegated under Section 4.3 of the
2077	2077	10 Clinical Psychologist Licensing Act, of a physician assistant
2078	2078	11 for a controlled substance in accordance with Section 303.05,
2079	2079	12 a written delegation, and a written collaborative agreement
2080	2080	13 required under Section 7.5 of the Physician Assistant Practice
2081	2081	14 Act of 1987, of an advanced practice registered nurse with
2082	2082	15 prescriptive authority delegated under Section 65-40 of the
2083	2083	16 Nurse Practice Act who issues a prescription for a controlled
2084	2084	17 substance in accordance with Section 303.05, a written
2085	2085	18 delegation, and a written collaborative agreement under
2086	2086	19 Section 65-35 of the Nurse Practice Act, of an advanced
2087	2087	20 practice registered nurse certified as a nurse practitioner,
2088	2088	21 nurse midwife, or clinical nurse specialist who has been
2089	2089	22 granted authority to prescribe by a hospital affiliate in
2090	2090	23 accordance with Section 65-45 of the Nurse Practice Act and in
2091	2091	24 accordance with Section 303.05 when required by law, or of an
2092	2092	25 advanced practice registered nurse certified as a nurse
2093	2093	26 practitioner, nurse midwife, or clinical nurse specialist who
2094	2094
2095	2095
2096	2096
2097	2097
2098	2098
2099	2099	HB2468 - 57 - LRB104 10667 AAS 20746 b
2100	2100
2101	2101
2102	2102	HB2468- 58 -LRB104 10667 AAS 20746 b HB2468 - 58 - LRB104 10667 AAS 20746 b
2103	2103	HB2468 - 58 - LRB104 10667 AAS 20746 b
2104	2104	1 has full practice authority pursuant to Section 65-43 of the
2105	2105	2 Nurse Practice Act.
2106	2106	3 (nn-5) "Prescription Information Library" (PIL) means an
2107	2107	4 electronic library that contains reported controlled substance
2108	2108	5 data.
2109	2109	6 (nn-10) "Prescription Monitoring Program" (PMP) means the
2110	2110	7 entity that collects, tracks, and stores reported data on
2111	2111	8 controlled substances and select drugs pursuant to Section
2112	2112	9 316.
2113	2113	10 (oo) "Production" or "produce" means manufacture,
2114	2114	11 planting, cultivating, growing, or harvesting of a controlled
2115	2115	12 substance other than methamphetamine.
2116	2116	13 (pp) "Registrant" means every person who is required to
2117	2117	14 register under Section 302 of this Act.
2118	2118	15 (qq) "Registry number" means the number assigned to each
2119	2119	16 person authorized to handle controlled substances under the
2120	2120	17 laws of the United States and of this State.
2121	2121	18 (qq-5) "Secretary" means, as the context requires, either
2122	2122	19 the Secretary of the Department or the Secretary of the
2123	2123	20 Department of Financial and Professional Regulation, and the
2124	2124	21 Secretary's designated agents.
2125	2125	22 (rr) "State" includes the State of Illinois and any state,
2126	2126	23 district, commonwealth, territory, insular possession thereof,
2127	2127	24 and any area subject to the legal authority of the United
2128	2128	25 States of America.
2129	2129	26 (rr-5) "Stimulant" means any drug that (i) causes an
2130	2130
2131	2131
2132	2132
2133	2133
2134	2134
2135	2135	HB2468 - 58 - LRB104 10667 AAS 20746 b
2136	2136
2137	2137
2138	2138	HB2468- 59 -LRB104 10667 AAS 20746 b HB2468 - 59 - LRB104 10667 AAS 20746 b
2139	2139	HB2468 - 59 - LRB104 10667 AAS 20746 b
2140	2140	1 overall excitation of central nervous system functions, (ii)
2141	2141	2 causes impaired consciousness and awareness, and (iii) can be
2142	2142	3 habit-forming or lead to a substance use disorder, including,
2143	2143	4 but not limited to, amphetamines and their analogs,
2144	2144	5 methylphenidate and its analogs, cocaine, and phencyclidine
2145	2145	6 and its analogs.
2146	2146	7 (rr-10) "Synthetic drug" includes, but is not limited to,
2147	2147	8 any synthetic cannabinoids or piperazines or any synthetic
2148	2148	9 cathinones as provided for in Schedule I.
2149	2149	10 (ss) "Ultimate user" means a person who lawfully possesses
2150	2150	11 a controlled substance for his or her own use or for the use of
2151	2151	12 a member of his or her household or for administering to an
2152	2152	13 animal owned by him or her or by a member of his or her
2153	2153	14 household.
2154	2154	15 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
2155	2155	16 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)
2156	2156	17 (720 ILCS 570/303.05)
2157	2157	18 Sec. 303.05. Mid-level practitioner registration.
2158	2158	19 (a) The Department of Financial and Professional
2159	2159	20 Regulation shall register licensed physician assistants,
2160	2160	21 licensed advanced practice registered nurses, and prescribing
2161	2161	22 psychologists licensed under Section 4.2 of the Clinical
2162	2162	23 Psychologist Licensing Act to prescribe and dispense
2163	2163	24 controlled substances under Section 303 and euthanasia
2164	2164	25 agencies to purchase, store, or administer animal euthanasia
2165	2165
2166	2166
2167	2167
2168	2168
2169	2169
2170	2170	HB2468 - 59 - LRB104 10667 AAS 20746 b
2171	2171
2172	2172
2173	2173	HB2468- 60 -LRB104 10667 AAS 20746 b HB2468 - 60 - LRB104 10667 AAS 20746 b
2174	2174	HB2468 - 60 - LRB104 10667 AAS 20746 b
2175	2175	1 drugs under the following circumstances:
2176	2176	2 (1) with respect to physician assistants,
2177	2177	3 (A) the physician assistant has been delegated
2178	2178	4 written authority to prescribe any Schedule III
2179	2179	5 through V controlled substances by a physician
2180	2180	6 licensed to practice medicine in all its branches in
2181	2181	7 accordance with Section 7.5 of the Physician Assistant
2182	2182	8 Practice Act of 1987; and the physician assistant has
2183	2183	9 completed the appropriate application forms and has
2184	2184	10 paid the required fees as set by rule; or
2185	2185	11 (B) the physician assistant has been delegated
2186	2186	12 authority by a collaborating physician licensed to
2187	2187	13 practice medicine in all its branches to prescribe or
2188	2188	14 dispense Schedule II controlled substances through a
2189	2189	15 written delegation of authority and under the
2190	2190	16 following conditions:
2191	2191	17 (i) Specific Schedule II controlled substances
2192	2192	18 by oral dosage or topical or transdermal
2193	2193	19 application may be delegated, provided that the
2194	2194	20 delegated Schedule II controlled substances are
2195	2195	21 routinely prescribed by the collaborating
2196	2196	22 physician. This delegation must identify the
2197	2197	23 specific Schedule II controlled substances by
2198	2198	24 either brand name or generic name. Schedule II
2199	2199	25 controlled substances to be delivered by injection
2200	2200	26 or other route of administration may not be
2201	2201
2202	2202
2203	2203
2204	2204
2205	2205
2206	2206	HB2468 - 60 - LRB104 10667 AAS 20746 b
2207	2207
2208	2208
2209	2209	HB2468- 61 -LRB104 10667 AAS 20746 b HB2468 - 61 - LRB104 10667 AAS 20746 b
2210	2210	HB2468 - 61 - LRB104 10667 AAS 20746 b
2211	2211	1 delegated;
2212	2212	2 (ii) any delegation must be of controlled
2213	2213	3 substances prescribed by the collaborating
2214	2214	4 physician;
2215	2215	5 (iii) all prescriptions must be limited to no
2216	2216	6 more than a 30-day supply, with any continuation
2217	2217	7 authorized only after prior approval of the
2218	2218	8 collaborating physician;
2219	2219	9 (iv) the physician assistant must discuss the
2220	2220	10 condition of any patients for whom a controlled
2221	2221	11 substance is prescribed monthly with the
2222	2222	12 delegating physician;
2223	2223	13 (A) (v) the physician assistant must have
2224	2224	14 completed the appropriate application forms and paid
2225	2225	15 the required fees as set by rule;
2226	2226	16 (B) (vi) the physician assistant must provide
2227	2227	17 evidence of satisfactory completion of 45 contact
2228	2228	18 hours in pharmacology from any physician assistant
2229	2229	19 program accredited by the Accreditation Review
2230	2230	20 Commission on Education for the Physician Assistant
2231	2231	21 (ARC-PA), or its predecessor agency, for any new
2232	2232	22 license issued with Schedule II authority after the
2233	2233	23 effective date of this amendatory Act of the 97th
2234	2234	24 General Assembly; and
2235	2235	25 (C) (vii) the physician assistant must annually
2236	2236	26 complete at least 5 hours of continuing education in
2237	2237
2238	2238
2239	2239
2240	2240
2241	2241
2242	2242	HB2468 - 61 - LRB104 10667 AAS 20746 b
2243	2243
2244	2244
2245	2245	HB2468- 62 -LRB104 10667 AAS 20746 b HB2468 - 62 - LRB104 10667 AAS 20746 b
2246	2246	HB2468 - 62 - LRB104 10667 AAS 20746 b
2247	2247	1 pharmacology;
2248	2248	2 (2) with respect to advanced practice registered
2249	2249	3 nurses who do not meet the requirements of Section 65-43
2250	2250	4 of the Nurse Practice Act,
2251	2251	5 (A) the advanced practice registered nurse has
2252	2252	6 been delegated authority to prescribe any Schedule III
2253	2253	7 through V controlled substances by a collaborating
2254	2254	8 physician licensed to practice medicine in all its
2255	2255	9 branches or a collaborating podiatric physician in
2256	2256	10 accordance with Section 65-40 of the Nurse Practice
2257	2257	11 Act. The advanced practice registered nurse has
2258	2258	12 completed the appropriate application forms and has
2259	2259	13 paid the required fees as set by rule; or
2260	2260	14 (B) the advanced practice registered nurse has
2261	2261	15 been delegated authority by a collaborating physician
2262	2262	16 licensed to practice medicine in all its branches to
2263	2263	17 prescribe or dispense Schedule II controlled
2264	2264	18 substances through a written delegation of authority
2265	2265	19 and under the following conditions:
2266	2266	20 (i) specific Schedule II controlled substances
2267	2267	21 by oral dosage or topical or transdermal
2268	2268	22 application may be delegated, provided that the
2269	2269	23 delegated Schedule II controlled substances are
2270	2270	24 routinely prescribed by the collaborating
2271	2271	25 physician. This delegation must identify the
2272	2272	26 specific Schedule II controlled substances by
2273	2273
2274	2274
2275	2275
2276	2276
2277	2277
2278	2278	HB2468 - 62 - LRB104 10667 AAS 20746 b
2279	2279
2280	2280
2281	2281	HB2468- 63 -LRB104 10667 AAS 20746 b HB2468 - 63 - LRB104 10667 AAS 20746 b
2282	2282	HB2468 - 63 - LRB104 10667 AAS 20746 b
2283	2283	1 either brand name or generic name. Schedule II
2284	2284	2 controlled substances to be delivered by injection
2285	2285	3 or other route of administration may not be
2286	2286	4 delegated;
2287	2287	5 (ii) any delegation must be of controlled
2288	2288	6 substances prescribed by the collaborating
2289	2289	7 physician;
2290	2290	8 (iii) all prescriptions must be limited to no
2291	2291	9 more than a 30-day supply, with any continuation
2292	2292	10 authorized only after prior approval of the
2293	2293	11 collaborating physician;
2294	2294	12 (iv) the advanced practice registered nurse
2295	2295	13 must discuss the condition of any patients for
2296	2296	14 whom a controlled substance is prescribed monthly
2297	2297	15 with the delegating physician or in the course of
2298	2298	16 review as required by Section 65-40 of the Nurse
2299	2299	17 Practice Act;
2300	2300	18 (v) the advanced practice registered nurse
2301	2301	19 must have completed the appropriate application
2302	2302	20 forms and paid the required fees as set by rule;
2303	2303	21 (vi) the advanced practice registered nurse
2304	2304	22 must provide evidence of satisfactory completion
2305	2305	23 of at least 45 graduate contact hours in
2306	2306	24 pharmacology for any new license issued with
2307	2307	25 Schedule II authority after the effective date of
2308	2308	26 this amendatory Act of the 97th General Assembly;
2309	2309
2310	2310
2311	2311
2312	2312
2313	2313
2314	2314	HB2468 - 63 - LRB104 10667 AAS 20746 b
2315	2315
2316	2316
2317	2317	HB2468- 64 -LRB104 10667 AAS 20746 b HB2468 - 64 - LRB104 10667 AAS 20746 b
2318	2318	HB2468 - 64 - LRB104 10667 AAS 20746 b
2319	2319	1 and
2320	2320	2 (vii) the advanced practice registered nurse
2321	2321	3 must annually complete 5 hours of continuing
2322	2322	4 education in pharmacology;
2323	2323	5 (2.5) with respect to advanced practice registered
2324	2324	6 nurses certified as nurse practitioners, nurse midwives,
2325	2325	7 or clinical nurse specialists who do not meet the
2326	2326	8 requirements of Section 65-43 of the Nurse Practice Act
2327	2327	9 practicing in a hospital affiliate,
2328	2328	10 (A) the advanced practice registered nurse
2329	2329	11 certified as a nurse practitioner, nurse midwife, or
2330	2330	12 clinical nurse specialist has been privileged to
2331	2331	13 prescribe any Schedule II through V controlled
2332	2332	14 substances by the hospital affiliate upon the
2333	2333	15 recommendation of the appropriate physician committee
2334	2334	16 of the hospital affiliate in accordance with Section
2335	2335	17 65-45 of the Nurse Practice Act, has completed the
2336	2336	18 appropriate application forms, and has paid the
2337	2337	19 required fees as set by rule; and
2338	2338	20 (B) an advanced practice registered nurse
2339	2339	21 certified as a nurse practitioner, nurse midwife, or
2340	2340	22 clinical nurse specialist has been privileged to
2341	2341	23 prescribe any Schedule II controlled substances by the
2342	2342	24 hospital affiliate upon the recommendation of the
2343	2343	25 appropriate physician committee of the hospital
2344	2344	26 affiliate, then the following conditions must be met:
2345	2345
2346	2346
2347	2347
2348	2348
2349	2349
2350	2350	HB2468 - 64 - LRB104 10667 AAS 20746 b
2351	2351
2352	2352
2353	2353	HB2468- 65 -LRB104 10667 AAS 20746 b HB2468 - 65 - LRB104 10667 AAS 20746 b
2354	2354	HB2468 - 65 - LRB104 10667 AAS 20746 b
2355	2355	1 (i) specific Schedule II controlled substances
2356	2356	2 by oral dosage or topical or transdermal
2357	2357	3 application may be designated, provided that the
2358	2358	4 designated Schedule II controlled substances are
2359	2359	5 routinely prescribed by advanced practice
2360	2360	6 registered nurses in their area of certification;
2361	2361	7 the privileging documents must identify the
2362	2362	8 specific Schedule II controlled substances by
2363	2363	9 either brand name or generic name; privileges to
2364	2364	10 prescribe or dispense Schedule II controlled
2365	2365	11 substances to be delivered by injection or other
2366	2366	12 route of administration may not be granted;
2367	2367	13 (ii) any privileges must be controlled
2368	2368	14 substances limited to the practice of the advanced
2369	2369	15 practice registered nurse;
2370	2370	16 (iii) any prescription must be limited to no
2371	2371	17 more than a 30-day supply;
2372	2372	18 (iv) the advanced practice registered nurse
2373	2373	19 must discuss the condition of any patients for
2374	2374	20 whom a controlled substance is prescribed monthly
2375	2375	21 with the appropriate physician committee of the
2376	2376	22 hospital affiliate or its physician designee; and
2377	2377	23 (v) the advanced practice registered nurse
2378	2378	24 must meet the education requirements of this
2379	2379	25 Section;
2380	2380	26 (3) with respect to animal euthanasia agencies, the
2381	2381
2382	2382
2383	2383
2384	2384
2385	2385
2386	2386	HB2468 - 65 - LRB104 10667 AAS 20746 b
2387	2387
2388	2388
2389	2389	HB2468- 66 -LRB104 10667 AAS 20746 b HB2468 - 66 - LRB104 10667 AAS 20746 b
2390	2390	HB2468 - 66 - LRB104 10667 AAS 20746 b
2391	2391	1 euthanasia agency has obtained a license from the
2392	2392	2 Department of Financial and Professional Regulation and
2393	2393	3 obtained a registration number from the Department; or
2394	2394	4 (4) with respect to prescribing psychologists, the
2395	2395	5 prescribing psychologist has been delegated authority to
2396	2396	6 prescribe any nonnarcotic Schedule III through V
2397	2397	7 controlled substances by a collaborating physician
2398	2398	8 licensed to practice medicine in all its branches in
2399	2399	9 accordance with Section 4.3 of the Clinical Psychologist
2400	2400	10 Licensing Act, and the prescribing psychologist has
2401	2401	11 completed the appropriate application forms and has paid
2402	2402	12 the required fees as set by rule.
2403	2403	13 (b) The mid-level practitioner shall only be licensed to
2404	2404	14 prescribe those schedules of controlled substances for which a
2405	2405	15 licensed physician has delegated prescriptive authority,
2406	2406	16 except that an animal euthanasia agency does not have any
2407	2407	17 prescriptive authority and a physician assistant shall have
2408	2408	18 prescriptive authority in accordance with the Physician
2409	2409	19 Assistant Practice Act of 1987 without delegation by a
2410	2410	20 physician. An A physician assistant and an advanced practice
2411	2411	21 registered nurse is are prohibited from prescribing
2412	2412	22 medications and controlled substances not set forth in the
2413	2413	23 required written delegation of authority or as authorized by
2414	2414	24 their practice Act.
2415	2415	25 (c) Upon completion of all registration requirements,
2416	2416	26 physician assistants, advanced practice registered nurses, and
2417	2417
2418	2418
2419	2419
2420	2420
2421	2421
2422	2422	HB2468 - 66 - LRB104 10667 AAS 20746 b
2423	2423
2424	2424
2425	2425	HB2468- 67 -LRB104 10667 AAS 20746 b HB2468 - 67 - LRB104 10667 AAS 20746 b
2426	2426	HB2468 - 67 - LRB104 10667 AAS 20746 b
2427	2427
2428	2428
2429	2429
2430	2430
2431	2431
2432	2432	HB2468 - 67 - LRB104 10667 AAS 20746 b